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ABSTRACT 
LIFE AFTER ADHESION: L-SELECTIN THROUGHOUT THE T CELL 
LIFESPAN 
 
by 
Abner Fernandez 
The University of Wisconsin-Milwaukee, 2013 
Under the Supervision of Dr. Douglas Steeber, Ph.D. 
 
Lymphocytes require antigenic encounter to activate and proliferate, 
eventually clearing the source of antigenic challenge. The peripheral lymph 
nodes (PLN) are the primary sites of antigenic encounter and thus the ability of 
lymphocytes to migrate to this tissue is a requirement for mounting effective 
immune responses. The process of lymphocyte migration to the PLN is known as 
the “adhesion cascade”. Specifically, lymphocytes are captured from the blood 
through the adhesion molecule, L-selectin, followed by CC chemokine receptor 7 
(CCR7)-mediated integrin activation, which ultimately results in cell 
transmigration into the PLN. Because the PLN is the site where antigenic 
encounter is most likely, we hypothesized that migration may induce pro-
proliferative signaling, mediated by L-selectin and conducted through CCR7. To 
study the potential “priming” effects of adhesion to antigen-mediated lymphocyte 
proliferation, spleen and PLN lymphocytes were subjected to in vitro 
transmigration and proliferation assays. Subsequently, multi-color flow cytometry 
analysis was used to examine treatment effects on the T cell population. Results 
showed that lymphocyte proliferation was significantly increased when L-selectin 
and CCR7 were activated simultaneously, compared to CCR7 activation alone.  
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Specifically, bulk tissue populations, as well as the CD4+ and CD8+ T cell subsets 
showed enhanced proliferation from both spleen and PLN sources at early and 
late time points. Additionally, to discern whether this enhanced proliferation may 
be a by-product of decreased apoptosis, an apoptosis assay was also performed 
at the same time points. Interestingly, L-selectin engagement resulted in 
protection from apoptosis for all T cell populations 72 hour following activation. 
However, this protective effect was not observed at the 36 hour time point. Taken 
together, these results suggest a role for L-selectin in enhancing T cell 
proliferation, at least in part, through an anti-apoptotic effect. This research will 
add to a better understanding of the regulation of lymphocyte proliferation and 
increase our knowledge of L-selectin signaling function. 
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Chapter 1: General Introduction 
 Migration and recirculation of lymphocytes are important prerequisites for 
generating an effective immune response. These processes are accomplished 
through the adhesion cascade in conjunction with chemoattractive factors. The 
role of L-selectin in lymphocyte migration and recirculation is well documented 
(1-4). However, its subsequent role late in the adhesion cascade remains 
unclear. In the peripheral lymph nodes (PLN), circulation of lymphocytes that 
have not encountered antigen (naïve cells) is primarily mediated by L-selectin 
and CCR7 (5). The PLN is where lymphocytes encounter their cognate antigen 
leading to activation and cell proliferation. The manipulation of CCR7 and L-
selectin is therefore an attractive avenue for either augmenting or attenuating the 
lymphocyte response. Limiting the responding cell population in states of 
pathological hyperactive immune response, as seen in autoimmune disorders, 
may alleviate the negative manifestations of such disorders. In contrast, a robust 
response may be desired in other cases such as infections and vaccinations. 
Recent results from our lab suggest that L-selectin engagement along with 
subsequent ligand (secondary lymphoid tissue chemokine, SLC, CCL21) binding 
of CCR7 enhances chemotaxis (6), and decreases apoptosis (7) L-selectin also 
contributes to the effectiveness of 2-integrin- mediated lymphocytic arrest (8-10). 
In neutrophils, L-selectin engagement also causes increased secretion of 
products that degrade pathogens, thus contributing to the effectiveness of the 
responses (11). Therefore, mounting evidence suggests that the initial step in 
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leukocyte migration involving L-selectin, contributes to the effectiveness of other 
subsequent steps such as transmigration and terminal effector response.  
1. T cells 
 T cells are white blood cells that arise from hematopoietic stem cells from 
red bone marrow (Figure 1). They are named T lymphocytes due to their 
maturation in the thymus (12). They are a subset of lymphocytes that express the 
T cell receptor (TCR, Figure 2)-a multi-molecular complex that recognizes 
specific peptide antigens normally presented by a self-cell expressing a marker 
known as the major histocompatibility complex (MHC, 13). Thus, T cells require a 
cognate antigen with a corresponding MHC to mount an effective or any 
response. T cells are divided into CD8+ or CD4+ T cells. T cells that express the 
CD4 co-receptor on their membrane are classified as helper T cells (Th cells). 
Their primary role is to coordinate the immune response, thus helping other 
immune cells in antigenic clearance and the maintenance of homeostasis (14). 
CD4+ T cells recognize antigens on antigen presenting cells (APC) which 
express the MHC-class II molecule. CD4+ T cells are primarily responsible for the 
clearance of pathogens of extracellular origin. The TCR of CD4+ T cells can 
recognize longer peptide antigens compared to the TCR of CD8+ T cells (15). 
CD8+ T cells on the other hand recognize peptide antigen along with the 
MHC-class I molecule which is a self-marker expressed by virtually all nucleated 
cells. CD8+ T cells are called cytotoxic T cells (Tc cells) due to their ability to 
secrete factors that result in cell death. CD8+ T cells are primarily responsible for 
the destruction of virally-infected or defective self-cells (tumors) and therefore 
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respond to intracellular challenges. CD8+ T cells are also responsive to CD4+ T 
cell-mediated co-stimulation. The biggest driver of CD8+ T cell proliferation is 
interleukin-2 (IL-2) secreted primarily by CD4+ T cells (16). 
The TCR expressed by the majority of T cells is a dimer of  and  chains 
that have arisen independently from each other through genetic rearrangement 
of their membrane distal variable regions. This provides for high variability and 
accounts for the unimaginable repertoire of variable regions specific for a 
multitude of peptide antigens. The TCR dimer is surrounded by 5 invariant chains 
of the CD3 complex: 2 , 1 , 1  and 2  chains. The CD3 molecules contain 
conserved cytoplasmic regions called Immunoreceptor-Tyrosine-based-
Activation-Motifs (ITAM) which are rich in potential phosphorylation residues. 
Interestingly, due to its short cytoplasmic tail, the TCR cannot generate 
intracellular signaling on its own and must therefore signal by coopting 
neighboring molecules such as the CD3 molecule. The co-receptor CD4 or CD8 
is also expressed, dependent on the T cell subset ,and interacts with MHC-class 
II or MHC-class I molecules, respectively. Finally, a CD28/CTLA-4 (Cytotoxic T-
Lymphocyte Antigen-4) dimer is also considered part of the TCR complex. CTLA-
4 is up-regulated in activated cells. CD28 stimulation results in an “on” signal 
while CTLA-4 stimulation results in an “off” signal (17). 
T cells react to antigens presented by other cells called APCs in a 
stepwise fashion. A cognate peptide for the TCR must be detected along with 
two other signals for proper T cell activation to occur. First, the 
TCR+peptide/MHC contact must be accompanied by a CD4+MHC-class II or 
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CD8+MHC-class I interaction; second, a co-stimulatory molecule, specifically the 
CTLA-4/CD28 dimer must also be stimulated by their respective ligands on the 
APC. Failure for any of these interactions to happen almost simultaneously 
results in T cells that are anergic and thus unable to activate (18). This anergy 
can still be overcome if the incoming signal is of high duration and quality (19). 
Once a T cell is stimulated properly, a kinase normally associated with the 
cytoplasmic tail of CD4 or CD8, light chain kinase (Lck), phosphorylates the 
ITAM’s of the  chains of CD3. The phosphorylated  chains in turn recruit zeta 
associated protein of 70 kDa (ZAP-70), which due to its close proximity to the 
inner leaflet of the cell membrane can now interact with scaffolding proteins such 
as linker of activated T cells (LAT) and the SH2 domain-containing leukocyte 
protein of 76 kDa (SLP-76). The final products of TCR signaling are the 
transcriptional up-regulation of proteins required for cell activation and 
proliferation and down-regulation of genes that are in opposition. Additionally, 
effector molecules to clear the immunogenic challenge are also transcribed, 
which include but are not limited to: IL-2 (20) and interferon- (21) for CD4+ T 
cells, or granzyme and perforin for CD8+ T cells (22). The signaling pathways 
that are normally utilized involve the Ras (rat sarcoma family of proteins, 23), 
PLC (phospholipase-C, 24), and NFB (nuclear factor kappa B proteins, 25).  
The result of TCR activation is the clonal expansion of that specific T cell 
lineage. In the best case scenario, the cause of antigenic challenge is eventually 
eliminated and the response of other T cell populations eventually down-
regulates the effector response (26). T cells that are products of antigen-induced 
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proliferation and have survived the initial response are called memory T cells (Tm 
cells). This memory pool is yet divided into at least two other subsets: effector 
memory T cells (Tem) which are sequestered in the tissue in which they are 
activated in, and central memory T cells (Tcm) which can still recirculate between 
the blood and the periphery (27). Their interaction with antigen in subsequent 
encounters creates a rapid and heightened response, resulting in the faster 
elimination of the immune challenge. 
2. T cell migration  
Lymphocytes require antigenic encounter to respond effectively, and 
antigenic encounter requires that these cells circulate throughout the whole 
organism. In the blood, the hemodynamic flow provides for maximal interaction 
between circulating lymphocytes and possible antigens. However, in areas of the 
body where flow dynamics is not dominant, such as in the PLN or cutaneous 
tissue, discrete and overlapping steps that capture lymphocytes from the blood 
must be established (28). Lymphocyte recirculation into the parenchyma is 
mediated by several overlapping steps with corresponding receptor 
engagements, intracellular responses, and ultimately a cellular physical 
response. In a homeostatic state, immune cell circulation in the PLN is mediated 
sequentially (Figure 3). First, the adhesion molecule L-selectin interacts with its 
ligands expressed on the endothelium (collectively called peripheral node 
adressins, PNADs) to arrest high velocity immune cells in the bloodstream. The 
cells, now decreased in their velocity, have the opportunity for the CCR7 receptor 
to interact with its ligand, CCL21. CCL21 is a soluble chemokine generated by 
local lymphoid tissue, thus its other name, secondary lymphoid tissue chemokine 
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(SLC). CCL21, although soluble, is sequestered on the vascular endothelium by 
glycosylaminoglycans (GAG’s, 29). The CCR7+CCL21 interaction triggers the 
change in conformation of 2-integrins (lymphocyte function associated antigen-
1, LFA-1), another class of adhesion molecule expressed on the lymphocyte 
(30). The change in conformation from a low affinity to a high affinity 
conformation of the integrin allows it to interact with its ligand, intercellular 
adhesion molecule-1 (ICAM-1), expressed on the endothelium to firmly arrest the 
cells. Finally, the lymphocytes transmigrate through the blood vessels into the 
PLN through processes such as cystoskeletal remodeling and basement 
membrane degradation (31). Once in the lymph node, lymphocytes may 
encounter their cognate antigen (activation). This interaction along with co-
stimulatory signals, results in clonal expansion (proliferation) and terminal 
differentiation, into either effector cells that mediate antigenic clearance (CD8+ T 
cells) or response-coordinating cells (CD4+ T cells). 
3. L-selectin 
 
L-selectin belongs to the selectin family of adhesion molecules and is 
expressed by all leukocytes (32). The E/P/L-selectins are multi-domain 
transmembrane proteins that have a ligand binding lectin domain, an epidermal 
growth factor-like domain, and short consensus repeat (SCR) domains (Figure 
4). The differences between the 3 selectin molecules rest on two factors, cell 
expression patterns and the number of SCR domains. E-selectin is expressed by 
inflamed endothelium and P-selectin is expressed by activated platelets and 
inflamed endothelium. Both E-and P-selectin have a varied SCR number 
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between species, normally ranging from 4-9, whereas L-selectin’s SCR is 
conserved between species at 2. Interestingly, all selectins seems to share 
ligands perhaps due to the common post-translational modifications required of 
their respective ligands. Naïve or circulating T cells have been shown to express 
higher levels of L-selectin compared to B cells (4). Because of migration 
differences in the spleen’s open circulation, and the PLN (separated from the 
blood by high endothelial venules (HEV)), the majority of cells in the PLN express 
high levels of L-selectin (33). Furthermore, naïve T cells express the highest 
levels of L-selectin, because activated T cells are normally sequestered in their 
activation sites to create an environment conducive to antigenic clearance, and 
thus are not required to recirculate (34) .  
L-selectin can be cleaved upon engagement at a membrane proximal region 
by a metalloproteinase, tumor necrosis factor -converting enzyme (TACE or 
ADAM17, 35). This cleavage results in a soluble form of the molecule, sL-
selectin, that can be detected in the plasma. It has also been shown that sL-
selectin can still bind to its ligands and perhaps serve to saturate L-selectin 
ligands on the endothelium not actively participating in cell-to-cell interactions 
(36). Interestingly, L-selectin-mediated tethering which normally happens 
between lymphocytes and the endothelium can also occur between leukocytes. 
This phenomenon of “secondary tethering” may help recruit more leukocytes to 
the endothelium, especially when the endothelium is inflamed (37).  
The ligands specific to L-selectin are varied and widespread among a variety 
of tissues and cells, especially in HEV of lymph nodes (31). The conserved 
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ligand structure is rich in posttranslational addition of modified carbohydrates, 
and so far 9 ligands that bind to L-selectin with varying affinities have been 
identified. There is a consensus that the molecule sialyl Lewis x (sLex), a 
tetrasaccharide, can bind to all 3 selectins (38). However, this seems to stem 
from a sulfated modification in sLex. Thus, structures that are sulfated, 
fucosylated and sialylated seem to be preferred L-selectin ligands. 
The intracellular domain of L-selectin is normally associated with ezrin-
radixin-moesin (ERM) and calmodulin (CaM) molecules that serve as a scaffold 
for spanning adjacent L-selectin molecules (39). The tail is also associated with 
-actinin which binds L-selectin to the actin cytoskeleton. This putative binding is 
proposed to orient L-selectin into a conformation that restricts access of TACE to 
the membrane proximal cleavage region. Once L-selectin binds to ligand, the 
ERM scaffold dissociates, leading to L-selectin cleavage and clustering of the 
cytoplasmic tail. Clustering of L-selectin upon engagement promotes 
downstream signaling effects such as oxidative burst, and an increase in kinase 
activity (10, 40-41). This suggests that L-selectin although a canonical adhesion 
molecule, may play a role in other pathways not restricted to adhesion. 
4.  CCR7 and Secondary Lymphoid Tissue Chemokine (SLC) 
Chemokines and their receptors are classified based on the position of the N 
terminus conserved cysteine residues (42). Chemokine receptors are serpentine 
transmembrane receptors that are often called G-protein coupled receptors due 
to their putative signaling mechanism (43). These receptors are normally 
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associated intracellullarly with a heterotrimeric G protein that dissociates upon 
ligand binding and results in subsequent activation of downstream signals.  
CCR7 (Figure 5) is a chemokine receptor that is involved in homeostatic 
recirculation of naïve lymphocytes and is highly specific for two ligands, CCL19 
(ELC) and CCL21 (SLC) (44). The former is primarily produced in secondary 
lymphoid tissues, and serves as a chemoattractive factor for recirculating 
lymphocytes (45-46). The CCR7 and SLC/ELC interaction is known to involve 
GAGs. GAGs serve as a scaffold upon which soluble SLC can bind (47). The 
downstream signaling invoked upon ligand binding has been shown to involve 
Ca+2 release mediated by CaM and tyrosine kinase activity (48). These signals 
converge downstream to facilitate nuclear translocation of NFB, among many 
other factors, resulting in enhanced transcription of a multitude of factors that 
enhance chemotaxis through cytoskeletal remodeling and cell polarization (49). 
Interestingly, the current body of knowledge also points to chemokine-driven 
enhanced effector effects. Chemokines and their receptors have been shown to 
serve a role in T cell development (50-51). Specifically for CCR7, it has been 
shown that intrathymic development of T cells is impaired in the absence of 
CCR7 (52). Furthermore, effector phenotypes such as the ability to lyse cells and 
to effectively proliferate can also be enhanced in the presence of CCR7 (53). 
Thus, CCR7 has been shown to have post-adhesive effects, which are more 
established than for L-selectin.  
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5. Lymphocyte surface receptor architecture and relationships 
 The cell membranes are very crowded places. It must be understood that 
membrane receptors are in close proximity with each other and impact the fluidity 
of the membrane ultrastructure (54). This is more so in cells that specialize in 
signaling such as a T cell. If we consider the number of clusters of differentiation 
(CD) antigens alone, one can only imagine the number of receptors on the T cell 
surface (55). Additionally, most of these receptors are present in high copy 
numbers, thus, creating a higher density of membrane proteins. The effect of 
receptors in close proximity to each other implies that they exert pressures and 
influences on each other. The crowding effect alone implies that a group of 
receptors must be down-regulated in order for another to be overexpressed. This 
may be the reason why cells constantly change their receptor repertoire, 
dependent on temporal and spatial contexts (56-58). 
 In the context of the TCR, CCR7 and L-selectin molecules, a direct 
association between the three of them is yet un-established. However, in regards 
to L-selectin and CCR7, we already alluded to their proposed close association. 
Previous studies have suggested that L-selectin activation enhances SLC 
induced chemotaxis (6). However, the Subramanian paper is the first paper to 
show such a relationship between L-selectin and CCR7 (6). Additionally, L-
selectin has also been shown to decrease apoptotic rates in transmigrating cells 
when the L-selectin molecule is previously activated (7). Additionally, the same 
report indicates an upregulation of the active monomer of NFB, p65, when cells 
that are transmigrated in the presence of SLC are previously exposed to an L-
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selectin activating antibody (7). Taken together, L-selectin activation prior to 
transmigration to SLC, may increase levels of signaling molecules that serve a 
role in proliferation and apoptosis. 
  In regards to receptor relationships in our context, association between 
the TCR and CCR7 is much more established. In a paper by Schaueble (59), it 
was shown that TCR-induced activation enhanced short term migration of 
peripheral blood mononuclear cells (PBMC). Another paper by Gollmer (60) also 
showed that SLC, a ligand for CCR7, can also contribute to CD4 co-receptor 
stimulation. Taken together, one can surmise that a relationship between these 
three molecules may exist.  
  
6. Hypothesis 
Based on the background information presented above, we propose that a 
relationship between L-selectin, CCR7 and TCR exists. We hypothesize that L-
selectin due to its increasing contributions to events far removed from initial 
tethering can also affect TCR-mediated proliferation, transduced through CCR7. 
Because of the role of L-selectin in moving lymphocytes from the sterile blood 
environment to the antigen rich parenchyma, we propose that L-selectin “primes” 
cells before antigenic encounter and thus hypothesize: 
1. That L-selectin can increase TCR-induced proliferation.  
2. That L-selectin exerts an anti-apoptotic effect on T cells 
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3. That L-selectin-mediated effects will be more pronounced in CD8+ T cells, due 
to a higher density of L-selectin in this subset, and in the PLN, due to the higher 
number of L-selectin positive cells in this tissue.                                                                                                                    
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Figure 1. T lymphocytes. T (matures in the Thymus) lymphocytes consist of two major subsets: CD4
+ and CD8
+
 cells. Both types have a common 
CD3 marker but possess the distinct co-receptors: CD4 or CD8. The TCR itself has variable regions specific to distinct antigenic peptide 
arrangements. Thus, T cells do not react to the same antigen. CD4
+
 T cells respond to peptides presented by antigen presenting cells (APC): 
dendritic cells primarily and phagocytic cells to a lesser extent. APCs display MHC-class II molecules which must be recognized by the CD4
+
 T cell 
for a response. CD8
+
 T cells respond to all nucleated cells (including APCs) but requires MHC-class I on the presenting cell for a response. CD4
+ 
T cells are coordinating cells of the immune system, signaling other immune cells to increase or decrease their respective responses relative to 
the challenge, thus they are called helper T cells. CD8
+
 
T cells act by directly killing cells presenting the proper antigen and MHC molecule, thus 
they are called cytotoxic T cells. 
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Figure 2. T cell receptor complex. The T cell receptor complex consists of multiple molecules. It utilizes the TCR dimer (most commonly an  and 
 chain) and the CD4/8 co-receptor to respond to antigen. The TCR dimer consists of two independent variable region (V) and two constant 
regions (C). The V region is responsible for antigen specificity. Once an antigen complementary to the V region is encountered and presented by a 
self-cell displaying the proper MHC, a response is initiated by the CD4/8 molecule’s light chain kinase (Lck) which induces phosphorylation of the  
chains of CD3.  This in turn recruits other signaling proteins to perpetuate kinase cascades: NFAT, NFB, MAPK, as the 3 most important kinase 
pathways. The antigen presentation to the TCR must be accompanied by a co-stimulatory signal which is transduced through the CD28+CTLA-4 
dimer. Co-stimulatory failure results in cells that are anergic. 
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Figure 3. Adhesion Cascade. Events that follow are typical at the interface between the blood and the vascular endothelium of the PLN. A 
lymphocyte is slowed down by L-selectin interacting with its ligand expressed on the vascular endothelium, resulting in lymphocyte rolling (1). The 
rolling cell’s chemokine receptor can now interact with its ligand that is sequestered on the endothelium by glycosylaminoglycans (2). This result in 
activation and a conformation change in the integrin receptor into an active form (3), which results in integrin-mediated firm arrest (4). Cells can 
then transmigrate into the underlying tissue (5).   
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Figure 4. Structure of human L-selectin. L-selectin consists of 4 extracellular regions along with a short (17 amino acids) cytoplasmic tail. The 
activation domain which is farthest from the cell is the lectin domain, followed by an epidermal growth factor (EGF)-like domain. It has 2 short 
consensus repeats (SCR), which is numerically conserved among species. A cleavage site that becomes accessible for a metalloproteinase 
during activation is present in the membrane proximal region. The short cytoplasmic domain which anchors the molecule to the actin cytoskeleton 
has putative binding sites for calmodulin and -actinin. Protein Kinase C is known to phosphorylate the two serine residues (circled).  Figure 
courtesy of Steeber et al., 2007 (31). 
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Figure 5. CC chemokine receptor 7 (CCR7) and its ligands. CCR7 is a chemokine receptor expressed by dendritic cells and T and B cells. The 
two known ligands are CCL19 (also known as ELC) and CCL21 (also known as SLC). The CCR7/SLC combination induces chemotaxis of 
lymphocytes into the parenchyma of the PLN, in cooperation with selectins and integrins. CCR7, as are all other chemokine receptors, is a G-
protein coupled receptor. Thus signaling involving G and G molecules is activated during receptor-ligand interaction.  
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Chapter 2: Characterization of T cell proliferation with L-selectin and CCR7 
activation 
 
1. Research design 
As previously covered in the introduction, lymphocytes need to be able to 
recirculate between the blood and lymphoid tissues to maximize the surveillance 
capacity of these cells and thus optimize conditions for mounting the adaptive 
immune response. L-selectin plays a crucial step in minimizing cell velocity in the 
blood-lymph node boundary. This “speed bump” effect increases cell contact with 
the vascular endothelium which polarizes the cell and induces its transmigration. 
As evident in the above description and from the adhesion cascade review in the 
introduction, L-selectin is not a stand-alone molecule, as compared to the TCR 
complex. Its effects towards the succeeding events after transmigration of the 
cell requires transduction via other molecules involved in the same pathway. 
Although direct studies of L-selectin contributions to vast arrays of T cell 
processes have been performed (61-62), most have centered on migratory 
capacity and none have dissected its contribution to TCR-induced proliferation; 
an event far removed from the initial L-selectin-mediated tethering and rolling 
steps.  
The direct activation of L-selectin and subsequent measurements of TCR-
independent proliferation is possible. However, we surmised that the signaling 
effects of L-selectin may be weak and transitory (63-64) and thus may not truly 
mirror its signaling effects in vivo. Furthermore, direct measurement of 
proliferation after L-selectin activation is not physiologically relevant, because 
most T cell activation occurs after the cell has migrated from the blood into the 
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lymph nodes, where the vast array of antigen presenting cells can directly 
interact with the transmigrated T cell (65-66). It is important to note that this 
mechanism of T cell activation is also possible in the spleen (67-68). However, 
the spleen is a predominantly B cell organ (69), where humoral immunity is more 
involved. Because T cell activation may come from both spleen and lymph 
nodes, regardless of the T cell proportion, both tissue T cell residents were 
isolated and analyzed for L-selectin-induced proliferative effects. To correct for 
the possible weak effect of L-selectin-mediated signaling which may be masked 
by “all or none” events such as TCR-induced proliferation; we coopted a 
molecule that serves with L-selectin in vivo. To this end we selected another 
molecule that has been shown to act with L-selectin in the adhesion pathway; 
CCR7 (70-71). In vivo, SLC is present on the surface of HEV in lymph nodes and 
thus its receptor, CCR7, is immediately activated after L-selectin-induced rolling 
(72). It has also been shown that activation of chemokine receptors on 
leukocytes can result in phosphorylation of serine residues in the cytoplasmic tail 
of L-selectin (73). A connection between L-selectin and CCR7 was recently 
shown by our lab with the demonstration of increased lymphocyte chemotaxis to 
SLC following L-selectin activation (6). CCR7 in this regard may serve as a 
molecular bridge between the initial L-selectin step and the terminal step of TCR-
induced proliferation. To test this idea, a in vitro assay was developed that 
mimics T cell transmigration and eventual TCR-induced activation and 
proliferation. This assay was performed by activating L-selectin via a specific 
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antibody, followed by chemotaxis in a transwell system in the presence of SLC 
and finally a terminal assay of anti-TCR-induced activation and proliferation.  
To measure levels of activation and proliferation empirically, resulting cell 
populations may be assessed with an activity assay such as the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The 
shortcoming of such an assay is that MTT reduction into the colored formazan 
product requires an active NADH dehydrogenase (74). NADH dehydrogenase is 
a mitochondrion-restricted enzyme (75-77). Mitochondrial enzymatic activity may 
be down regulated in cells that have been exposed to sustained proliferative 
signals and cell-to-cell inhibition due to volume restrictions and hypoxic 
conditions (78-79). Furthermore, the use of an organic hydrophobic substance 
such as dimethyl sulfoxide (DMSO) to solubilize the crystals is problematic, 
because hydrophobic substances, especially DMSO readily diffuses into the 
vapor phase. The MTT assay also requires a response/cell standard. Because 
this assay is based on enzymatic activity, cell populations from the same 
conditions must be used for analysis and as standards. Analyzing subset effects 
also requires homogenous cell purification prior to the assay, which is time and 
resource intensive. Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) 
is an intracellular fluorescent stain (80). In the CFDA-SE form it is non-
fluorescent and readily passes through the hydrophobic cell membrane (81). 
Once it is in the cytoplasm, intracellular esterases cleave it into the 
carboxyfluorescein succinimidyl ester (CFSE) form. CFSE is fluorescent with an 
excitation/emission signature of 492nm/517nm. Furthermore, CFSE is not readily 
21 
 
 
 
permeable and can be covalently linked to protein residues in the inner leaflet of 
the cell membrane. Thus in its CFSE form it is restricted to the intracellular 
compartment. Another advantage of CFSE is that only viable cells can convert 
and retain it. The intracellular esterases responsible for its conversion are also 
not mitochondrion restricted. Furthermore, cell division results in a stoichiometric 
halving of the CFSE signal (82). Thus, each progeny population will have a 
CFSE fluorescence intensity signature of approximately half of the previous 
generation. However, optimal concentrations of CFSE must be empirically 
determined because excessive amounts, although non-toxic, will render the cells 
anergic (83). 
 The monoclonal antibody (mAb) against the lectin domain of L-selectin, 
LAM1-116, was generated previously and has been shown to induce homotypic 
adhesion between lymphocytes in vitro (10). Interestingly another L-selectin 
antibody generated from the same fusion, LAM1-101, recognizes the EGF/SCR 
region of the molecule and has been shown to induce no phenotypic effects on 
cells. In relation to this thesis, we utilized LAM1-116 as an activating anti-L-
selectin antibody and LAM1-101 as a negative control antibody. The superiority 
of using two antibodies generated against the same molecule, but specific to two 
different domains with corresponding phenotypic effects, has huge advantages. 
Using isotypic antibodies that can bind to the same molecule with approximately 
equal affinity is superior to assays utilizing non-specific mouse antibodies, most 
notably in cases where non-specific mouse IgG is used. Alternatively activation 
of L-selectin with phorbol myristate acetate (PMA) could have been used but its 
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relevance in vivo would have been lost, since the mechanism of PMA activation 
is via an inside-out signaling mechanism utilizing protein kinase C (PKC, 84), 
which is atypical of L-selectin function in the context of migration. A different 
approach for activating L-selectin would have been to utilize its natural ligands. 
However, a preferred or dominant L-selectin ligand has still not been identified 
(32). Instead, L-selectin is known to bind to a vast array of ligands, including 
ligands that have been shown to bind to other adhesion molecules, such as P-
selectin glycoprotein ligand-1 (PSGL-1), a ligand that can bind to all selectin 
molecules (85). Some reports have also shown that L-selectin can be activated 
by binding molecules known to have been incorporated post-translationally, such 
as sulfatides or glycoproteins. However, these modifications are not unique to L-
selectin ligands and their activaty may require other molecules besides L-selectin 
such as sulfatide receptors.  
A transwell or transmigration system mimics the interface between blood 
and the parenchymal tissues such as the PLN (86). The system that we used has 
an upper and lower chamber, corresponding to the blood and parenchyma 
respectively. The bottom chamber can be loaded with chemokines or any other 
putative chemoattractive substance, which can be separated from the lower 
chamber with polycarbonate membranes with varying pore sizes. The pore size 
is important because transmigration into the periphery requires T cell polarization 
and cytoskeletal rearrangement (87). If a smaller pore size compared to the 
cellular diameter of the population of interest is used, only cells that actively 
transmigrate through cellular polarization and rearrangement can be found in the 
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lower chamber after a pre-determined amount of time.  The time utilized for this 
transmigration/chemotaxis assay must be determined empirically because the 
chemokine or any chemoattractive substance will readily diffuse between 
chambers, ultimately resulting in equilibrium where no chemical gradient is 
present and thus resulting in cell inertia or worse, reverse transmigration, which 
may happen in cases where the chemical has partial solubility and less density 
than the media. The limitation of the transmigration assay is that the number of 
cells that transmigrate dictates any subsequent assays. In our case, the volume 
of the chambers is quite small and thus the numbers of cells available for the 
subsequent proliferation assay is limited. Another possible challenge is that the 
transmigrated cell population may have a preponderance to favor a specific T cell 
subset. If this is the case, the proliferation analysis will already have an 
established bias towards the dominant transmigrating subset. To correct for this 
population issue and still maintain research integrity of paired tests, the assays 
were performed one tissue at a time and multiple wells were utilized per 
treatment. Briefly, there were 4 transmigration treatments: 1) untreated cells, 2) 
cells transmigrated in the presence of SLC, 3) cells previously treated with 
activating LAM1-116 mAb and transmigrated in the presence of SLC, and 4) cells 
previously treated with control LAM1-101 mAb and transmigrated to SLC. Wells 
coinciding with the same treatment were pooled to generate enough cells for the 
next assay. Subset analysis by flow cytometry was also performed after pooling 
to guard against any subset bias. 
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The cells from the transmigration assay were subsequently exposed to a 
TCR-induced proliferation assay using monoclonal antibodies against two trans-
membrane proteins, the TCR-associated epsilon subunit of the CD3 complex and 
the co-stimulatory molecule, CD28. Cross linking of surface proteins, especially 
those with signaling capabilities such as CD3 and CD28, provokes downstream 
signaling that induces proliferation (88-89).  Both antibodies were needed 
because ligation of CD3 alone only invokes the initial activation of T cells (90-91) 
whereas co-ligation of CD28 is needed for sustained cell proliferation (92). 
Because TCR signaling puts T cells under extreme duress, time points were 
empirically determined to assess the peak levels of proliferation.  
Cell analysis was performed using a flow cytometer. A flow cytometer has 
a distinct advantage of analyzing high numbers of cells in multiple populations in 
minimal amounts of time. Antibodies with conjugated fluorescence molecules or 
fluorescent dyes specific to the cell of interest can be detected via a flow 
cytometer. An important property of flow cytometry that allows for detection of 
labeled cells one at a time is called hydrodynamic focusing. Hydrodynamic 
focusing is similar to liquid chromatography albeit without a stationary phase. 
Two layers of fluid diameters are aligned; the outer layer called the sheath 
volume pushes the inner fluid diameter layer which makes up the sample. Cell 
suspensions are pushed through the flow cytometer system via differing 
velocities of a buffering liquid, hence the word “flow”. The sheath diameter of fluid 
pushing the cells is a product of its velocity. Slower flow is a product of a smaller 
sheath fluid diameter, hence a larger sample fluid diameter. When the sheath 
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diameter increases, the sample fluid diameter decreases resulting in greater 
force and greater sample velocity. Due to the small sheath diameter, the inner 
cell suspension can be optimized to a diameter slightly larger than the cell of 
interest. This results in one cell per unit volume. The fluorescently labeled cells, 
one at a time are then passed through an excitation source and their resulting 
emission, which is of a low magnitude is amplified via a series of photomultiplier 
tubes. This system does not just detect cell surface proteins but with a cell 
permeabilization step can also detect intracellular molecules.  
 
2. Materials and Methods 
 
i. Animals and Tissues 
 
C57BL/6 mice (Jackson Labs, Bar Harbor, ME) were raised in pathogen-free 
conditions with unrestricted access to food and water. Mice were used at 2-4 
months of age. Cells isolated from the spleen, and inguinal and axillary lymph 
nodes were exclusively used for all experiments. All tissues were dissected 
under aseptic conditions. Mice were sacrificed via CO2 inhalation. All animal 
procedures were approved by the Institutional Animal Care and Use Committee 
of the University of Wisconsin-Milwaukee.  
ii. Lymphocyte Isolation 
 
Single-cell suspensions of mouse splenocytes were prepared by mechanical 
homogenization of the spleen while in suspension with 0.1 M phosphate buffered 
saline (PBS), and filtration of debris through a 120 m pore sized nylon mesh 
(Elko Filtering, Miami FL). Red blood cells were lysed in a KHCO3-buffered 0.15 
M NH4Cl solution. The resulting red blood cell-free cell solution was filtered, 
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washed and centrifuged twice in PBS. All cells were re-suspended in Dulbecco’s 
PBS (DPBS, Life Technologies, Carlsbad CA) unless otherwise stated. 
Lymphocytes from bilateral inguinal and axillary lymph nodes were similarly 
prepared with the exception of the red blood cell lysis step. Cell counts were 
determined using a 0.04% trypan blue exclusion assay with a hemacytometer. 
Dead cells have permeable membranes and thus will present with a blue 
cytoplasm which can be excluded from the resulting cell count. 
iii. CFSE Staining 
 
Lymphocytes (10 x 106 cells/mL) from the spleen and lymph nodes that were 
isolated as previously described, were incubated for 15 minutes at 37°C in 0.25 
M of CFDA-SE (Molecular Probes, Carlsbad CA) in pre-warmed DPBS, with 
regular mixing.  The required cell and CFSE concentrations were previously 
determined empirically. The concentrations used gave high CFSE Mean 
Fluorescence Intensity (MFI) of equal to or greater than 103, yet still provided 
responsive reporter cells. Resulting suspensions were washed twice with DPBS 
supplemented with 10% Heat-Inactivated Fetal Bovine Serum (HI-FBS, Life 
Technologies). HI-FBS was needed to quench excess CFSE, minimizing its anti-
proliferative effects. The cells were then re-suspended in RPMI-1640 medium 
(Life Technologies) supplemented with 10% HI-FBS, and allowed to equilibrate at 
a 37°C water bath for 30 minutes. The previous 30 minute step at that 
temperature allows the cells to cleave the diacetate moiety of CFDA-SE and 
covalently link CFSE intracellularly, allowing for staining stability and 
reproducibility. All antibodies used in the subsequent experiments were 
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purchased from BD Pharmingen (San Jose, CA) unless otherwise stated. Flow 
cytometric subset analysis for L-selectin expression was then undertaken, using 
anti-mouse CD4 (Clone:RM4-5) conjugated to Phycoerythrin (PE), anti-mouse 
CD8 (Clone:53-6.7) conjugated to AlexaFluor 647, and biotin conjugated LAM1-
116 monoclonal antibody against L-selectin, which was revealed with a PE-Cy5.5 
fluorophore conjugated to avidin. Briefly, LAM1-116 mAb and LAM1-101 mAb 
were isolated from the ascites fluid of RAG-1-knockout mice injected in the 
peritoneum with the hybridomas for each antibody. The antibodies were isolated 
and concentrated from ascites by NH4SO4 precipitation, followed by extensive 
dialysis with column buffer (0.1 M NaC2H3O2, pH 5). The antibodies were then 
purified by protein G affinity chromatography and released with elution buffer (0.1 
M glycine-HCl, pH 2.8). The eluted antibody fractions were neutralized by 1M 
Tris, pH 9.0.  The neutralized chromatography fractions were pooled and after 
extensive 0.1 M PBS dialysis, the antibody purity was confirmed by reducing 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE). 
Aliquots of the purified mAbs were divided into fractions and stored at -20°C until 
use. Biotinylated LAM1-116 was prepared by mixing 0.15 mg of EZ-Link®-NHS-
LC-Biotin (Thermo Scientific, Waltham MA) per 1 mg of purified antibody, for one 
hour at room temperature. Free biotin was removed from antibodies by extensive 
dialysis with 0.1 M PBS. The antibody concentrations of the pooled fractions 
were determined using a NanoDrop® scanning spectrophotometer (Thermo 
Scientific) at OD280. The resulting solutions were re-suspended in 0.1 M PBS and 
stored at 4°C until use.  
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L-selectin staining of CFSE-treated cells was done 12 hours post CFSE 
staining. L-selectin staining was undertaken at the 12 hour time point because 
initial CFSE fluorescence interfered with any flow cytometric analysis by bleeding 
into multiple fluorescent channels that was not correctable by instrument 
compensation. To ensure that L-selectin was not prematurely shed by CFSE-
labeled cells during the 12 hour waiting period, all samples were stored at 4°C 
until L-selectin staining was performed. Optimum antibody concentrations were 
determined empirically through fluorescence titration studies. All working 
antibody solutions were diluted in PBS+ 2% NHS. All antibody staining was 
carried out on ice for 30 minutes. Non-specific mouse IgG mAbs conjugated to 
the same fluorophores (Southern Biotech, Birmingham, AL) were utilized as non-
specific isotypic controls in all cases. Unbound antibodies were removed prior to 
flow analysis with a terminal wash step using PBS supplemented with 2% normal 
horse serum (Thermo Scientific). All flow cytometric acquisitions were performed 
using a BD FACSCalibur instrument (BD Biosciences, San Jose, CA). Cells were 
gated on the population that showed forward and side light scatter properties of 
mononuclear cells. At least 5000 events were collected for each sample. All 
subsequent data were analyzed with CellQuestTM Pro (BD Biosciences) software.  
iv. Chemotaxis Assay 
CFSE-labeled lymphocytes (1 x 106 cells/mL), re-suspended in RPMI-
1640 supplemented with 0.1% bovine serum albumin (DNAse/RNAse/Protease 
free BSA (Fraction V), Fisher Scientific, Waltham MA) were then subjected to a 
chemotaxis assay, using the 48 well Neuroprobe System (Neuroprobe Inc., 
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Gaithersburg, MD). The lower chamber was loaded with 50 L of RPMI-
1640+0.1% BSA, with or without 500 ng/mL of SLC (Peprotech, Rocky Hill, NJ). 
The SLC concentration used has been shown to induce chemotaxis of at least 
50% of input T cells (6). The whole apparatus was then assembled with a 5 m 
pore size polycarbonate membrane separating the upper and lower chambers. 
The upper chamber was then loaded with 3 treatment groups of cells (5 x 104 
cells/50 L/well). The different treatments were: cells in media alone, cells 
treated with 10 g/mL of LAM1-116 mAb, and cells treated with 10 g/mL of 
LAM1-101 mAb. The appropriate antibodies were added to the cells prior to 
chemotaxis. Cells were then allowed to chemotax in a humidified, 37°C, 5% CO2 
incubator (Thermo Scientific) for one hour. The chemotaxed cells from the same 
treatment were pooled and adjusted to a final cell concentration of 2.5 x 105 
cells/mL, in RPMI-1640 medium supplemented with: 0.1% BSA, 100 U/mL 
penicillin, 100 g/mL streptomycin, 2 mM L-glutamine and 55 M -
mercaptoethanol (all supplements were from Life Technologies). -
mercaptoethanol was not initially used due to the possibility of disulfide bond 
reduction in the presence of this chemical. SLC and L-selectin have multiple 
disulfide linkages that may be reduced and thus may result in the loss of 
functional secondary structure of these two molecules. However, -
mercaptoethanol was ultimately used after LAM1-116 mAb and SLC treatment to 
prevent the cellular aggregation inherent in long-term subculturing of primary 
cells. Prior to incubation in the presence of anti-TCR antibodies, lymphocyte 
subset analysis via flow cytometry was then performed using PE-conjugated anti-
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mouse CD4 and AlexaFluor 647-conjugated anti-mouse CD8 mAbs. This 
analysis was performed prior to the cells being used for the subsequent assays. 
v. Proliferation Assay 
 
The previously pooled chemotaxed cells were then subjected to a TCR-
induced proliferation assay. A sterile 96 well round-bottom assay plate (Thermo 
Scientific) was coated with low endotoxin/NaN3-free grade anti-mouse CD3 
(Clone:145-2C11) and anti-mouse CD28 (Clone:37.51) mAbs, both used at 2 
g/30 L diluted in 37°C DPBS. The maximum amount of antibody that can bind 
to round-bottom wells has been shown to be approximately 3 g/well (93). After 
90 minutes in a 37°C, 5% CO2 incubator, unbound antibodies were removed by 
washing the wells with 4°C DPBS. Cells from the previous assay were then 
added to each well at a density of 5 x 104 cells/200 L, and were allowed to 
proliferate in a 37°C, 5% CO2 incubator. Cells were collected at the 36 and 72 
hour time points and were subsequently analyzed for proliferation and apoptosis. 
Proliferation effects per subset were analyzed singly using anti-mouse CD4 and 
anti-mouse CD8 mAbs both conjugated to AlexaFluor 647 and in some cases, 
double staining with the same Alexa Fluor conjugated anti-mouse CD8 but with 
an anti-mouse CD4 conjugated to PE. Cells that displayed increasing side and 
forward light scatter, a property of proliferating lymphoblasts, were included in the 
live cell gating. Histograms of proliferating cells were compared to a 
corresponding CFSE-stained cell sample without TCR-induced proliferation. A 
similarly prepared CFSE sample must be utilized because the fluorescence 
intensity of CFSE exhibits some time-dependent decay. Autofluorescence 
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correction for negative cells was done using corresponding samples not labeled 
with CFSE. Thus, the area of the histogram flanked by the non-proliferated 
sample and the unlabeled cell sample were considered to be the proliferating 
population. The percentages of the proliferating population of the SLC-treated 
samples were compared to the sample exposed to media alone.  
vi. Data Analysis 
 
After analyzing the raw data for homogeneity of variance with the Bartlett 
test and normality with a Q-Q line plot, deviations were detected that proved the 
raw data unusable. To correct for these departures from normality and variance 
all data were normalized as follow: 
%Proliferation Enhancement = (frequency of cells proliferating in the 
treated sample/frequency of proliferating cells in the untreated sample) *100  
In some cases the frequency of each cell division was also determined. 
Manual gates were drawn to peaks corresponding to the area flanked by the 
negative and positive CFSE sample. Each subsequent peak had to display 
relative fluorescence intensity approximately half of its parent population to be 
considered for analysis.  
Transformed data were subjected to normality and variance tests, through 
Q-Q line plot and Bartlett tests, respectively. No significant departures were 
noted or the residuals of the outliers did not impact the outcome of the factors. 
Data were then analyzed with one-way ANOVA. If data sets showed significant 
variance (p < 0.05), further analysis between groups was performed using the 
Tukey Honestly Significant Difference (HSD) test. A P value of less than 0.05 
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was considered significant. Pearson correlation was also performed between 
Proliferation versus % L-selectin positive cells. All summary data are displayed 
with standard error from the mean (SEM) bars. All data analysis was performed 
using R 2.15.2 (R Foundation for Statistical Computing, Vienna, Austria). 
3. Results 
i. Data transformation to correct for statistical bias in raw data from proliferation 
studies. 
 
 Cells labeled with CFSE and subjected to the transmigration and 
proliferation assays were analyzed by flow cytometry. Raw data that was 
collected provided a spread that affected data analysis. In the bulk lymphocytic 
proliferation assays at the 36 hour time point for the spleen, the numbers that 
corresponded to TCR-induced proliferating cells for the CFSE-labeled sample 
untreated with SLC or mAb, ranged from 38.7% to 94.36%. This was an 
important data spread because the most responsive population treated with SLC 
and LAM1-116 simultaneously, also had a big data spread of 48.3% to 98%. 
Using a Q-Q plot to determine normality, outliers that impacted the outcome of 
the dependent factors were detected. Furthermore, the Bartlett test for 
homoscedasticity also yielded departures from variances that were not a product 
of normal distribution. In other instances, where data were normally distributed 
and homogenous variances were established, the results yielded a P value of 
less than 0.05. However, upon closer examination using the post hoc Tukey HSD 
test, the significant finding was the result of the negative sample exhibiting lower 
proliferation than the treated samples, with no variances between SLC-treated 
samples, which rendered our data set differences statistically insignificant. To 
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eliminate the departures from normality and homoscedasticity, we transformed 
the data sets by comparing all effects to the proliferated but untreated control. As 
such, for proliferation, the equation Treatment (SLC, SLC+LAM1-116, and 
SLC+LAM1-101)/Control * 100, was used to generate a proliferation index. 
Numbers lower than 100% indicate a lower proliferative effect than the control 
and numbers greater than 100% indicate effects higher than the control. The 
added benefit of this transformation is that the comparisons between samples 
are now restricted to 3 samples treated with SLC, narrowing the dependent 
variable to L-selectin activation alone. This comparison is utilized for the 
remainder of these studies, unless otherwise stated. 
ii. Spleen and PLN lymphocytes treated with SLC and LAM1-116 mAb have 
increased proliferation at 36 and 72 hours post-TCR stimulation  
 
 To mimic in vivo conditions, we utilized mAbs to CD3 and CD28 to create 
a condition, parallel to that encountered by T cells during MHC-restricted 
antigenic challenge. As expected, all samples showed enhanced proliferation 
over the control, likely as a product of SLC treatment (Figure 6). In all cases, SLC 
treated samples pre-treated with the L-selectin activating LAM1-116 mAb 
showed the greatest enhancement in proliferation (Figure 6 C and G). In the 36 
hour spleen sample, the variance between the 3 treatment group samples 
compared to the control was significant at P=0.04 (n=10). Interestingly, Tukey’s 
HSD test tended towards a significant difference between the SLC+LAM1-116 
mAb treated sample versus the SLC treated sample with a P=0.06 (n=10). This 
was the same in comparing the LAM1-116 mAb treated sample to the LAM1-101 
mAb treated sample with a P=0.09 (n=10). In the PLN sample at the same period 
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of 36 hours, the variance was significant at P=0.01 (n=9) with Tukey’s HSD test 
showing P=0.01 (n=9) and P=0.04 (n=9) for the LAM1-116 mAb treated sample 
compared to SLC alone and the LAM1-101 mAb treated sample, respectively. 
Visually analyzing the histograms also showed a discernible increase in the late 
cell division population ( by the number of peaks, and the height of the terminal 
peak) of the LAM1-116 mAb-treated samples as compared to other samples, in 
both the spleen and PLN. We expected proliferation effects to be higher in the 
PLN, because this secondary lymphoid organ is T cell rich compared to the 
spleen, and T cells as a population have higher frequencies of L-selectin positive 
cells. During the early post-stimulation period of 36 hours, this was the case with 
proliferation enhancement in the PLN ranging from 115%-134% as compared to 
the range in the spleen of 105%-116% (Figure 7). 
Interestingly, at 72 hours post-TCR stimulation, treatment groups showed 
a general decrease in proliferation enhancement (Figure 8). The decrease in 
proliferation of the 72 hour samples does not seem to be a product of time 
sensitization but rather a by-product of samples reaching or approaching 
asymptotic growth at the later times post-TCR stimulation, indicating all cell 
populations have reached close to maximal divisions (Figure 8). This seems to 
be a shortcoming of our data transformation which we will address later. 
At the 72 hours post-TCR stimulation time point, both the spleen and the 
PLN showed an almost equal level of enhanced proliferation with ranges of 
108%-117% and 107%-120%, respectively. The ANOVA test showed significant 
variances for both spleen and PLN at P=0.015 (n=7) and P=0.016 (n=6), 
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respectively (Figure 9). However, regardless of the decreased proliferative 
enhancement effect of SLC and LAM1-116 mAb treatment at 72 hours post-
stimulation, in comparison to the similarly treated 36 hour sample, Tukey’s HSD 
test show significant increases for the LAM1-116 mAb treated splenic sample, 
with a P=0.02 (n=7) compared to SLC treatment alone, and a P=0.04 (n=7) 
compared to LAM1-101 mAb treatment.  
iii. Transmigrating cell subsets show homogeneity regardless of treatment 
 The significant levels of proliferation in bulk populations at the 36 and 72 
hour mark gave us an impetus to determine if these enhanced proliferation levels 
were present in both the CD4+ and CD8+ T cell subsets. We initially chose to 
focus on T cells due to the higher density of L-selectin and CCR7 expression in 
these cells in comparison to B cells. Furthermore, activation in B cells seems to 
result in CCR7 up-regulation which is in opposition to the T cell-specific effect 
(94). 
 The transmigration step before the proliferation assay was a potential 
pitfall because it was possible that there would be a transmigration bias towards 
a particular subset and thus affect subset proliferation results. Fortunately, there 
were no statistical variances between treatment groups as to the proportion of 
transmigrated CD4+ and CD8+ T cell subsets as shown in representative dot 
plots (Figure10, upper left and lower right quadrant numbers) or as shown in 
summary data (Figure 11). Specifically, the frequency of transmigrated splenic 
CD4+ T cells regardless of treatment was not varied (n=7, P=0.91) at a range of 
21±1.2%. The results were similar for splenic CD8+ T cells at a range of 17±2% 
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with a variance of P=0.98 (n=7). PLN CD4+ T cells also showed no variance 
between treatments at P=0.99 (n=7). CD8+ T cells from the PLN also were not 
statistically varied at a P=0.97 (n=7). 
 The homogenous proportions of both T cell subsets in all treatments 
allowed us to undertake the subsequent experiments with ease and without bias  
iv. Spleen and PLN CD4+ T cells treated with SLC and LAM1-116 mAb have 
increased proliferation at 36 and 72 hours post-TCR stimulation 
 
 To determine the effects of L-selectin activation among the CD4+ T cell 
subset, we labeled samples for CD4 and determined the frequency of 
proliferating cells in the treatment groups as discussed in the previous 
experiments. After gating for cells that exhibited the side and forward light scatter 
properties of mononuclear cells, CD4+ T cells as distinguished by PE-conjugated 
antibody staining, were analyzed for CFSE intensity, to examine proliferation 
using the same strategy as outlined in the previous experiments. A 
representative experiment illustrating an increase in CD4+ T cell proliferation as 
compared to the negative control is shown in Figure 12. Comparing the SLC-
treated sample to the negative control, an increase from 61% to 66% was found 
in the spleen sample (Figures 12 A and B), and an increase from 44% to 48% 
was found in PLN samples (Figures 12 E and F). The SLC+LAM1-101 mAb-
treated samples showed similar increases in comparison to the negative control 
for both splenic and PLN samples but show an equal increase in proliferation 
when compared to the SLC-treated sample alone (Figures 12 A and D, and 
Figures 12 E and H, respectively). Interestingly, the SLC+LAM1-116 mAb-treated 
samples showed the highest increases in proliferation (12 C and G). 
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 The increases outlined above were statistically significant, as shown in the 
summary data (Figure 13), with variance in the spleen sample, after data 
transformation, at P=0.01 (n=7) and for the PLN sample with P=9x10-4 (n=7). In 
the spleen, the increase in the SLC+LAM1-116 mAb-treated sample compared to 
the SLC-treated cells was significant at P=0.01 (n=7), or with the SLC+LAM1-101 
mAb-treated sample P=0.03 (n=7). In the PLN, the same levels of significance 
were noted with P=0.01 (n=7) between LAM1-116 mAb treated SLC 
transmigrated cells versus SLC-treated alone transmigrated cells. The increase 
in proliferation for the LAM1-116 mAb treatment as compared to the LAM1-101 
mAb treatment was also statistically significant with a P=0.02 (n=7). 
 In the samples analyzed 72 hours post stimulation, all samples showed 
increased proliferation over the 36 hour sample. In the representative histograms 
shown in Figure 14, all SLC-treated samples showed appreciable increases in 
proliferation when compared with the untreated negative control. As expected, 
the LAM1-116 mAb-treated samples showed the highest increase in proliferation.  
 The summary data (Figure 15) reflects the above described 
enhancements with the splenic and PLN samples showing significant variance at 
P=0.01 (n=5) and P=0.03 (n=5), respectively. In the spleen, the Tukey’s HSD test 
showed statistical difference between the SLC- vs. SLC+LAM1-116 mAb-treated 
samples with a P= 0.01 (n=5). A similar difference in the same tissue was found 
between the SLC+LAM1-101 mAb- vs. SLC+LAM1-116 mAb-treated samples 
with a P=0.03 (n=5). In the PLN, the Tukey’s HSD test showed significant 
differences between the LAM1-116 mAb-treated sample vs. SLC alone with a 
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P=0.05 (n=5), and with the LAM1-101 mAb-treated sample with a P=0.04 (n=5). 
Taken together, these results strongly support the idea that L-selectin activation 
prior to SLC-induced chemotaxis significantly enhances CD4+ T cell proliferation 
through the TCR, regardless of tissue origin.  
iv. Spleen and PLN CD8+ T cells treated with SLC and LAM1-116 mAb have 
increased proliferation at 36 and 72 hour post-TCR stimulation 
 
 Analysis of CD8+ T cells showed enhancements that mirrored the effects 
seen in CD4+ T cells. Representative data (Figure 16) showed increased 
proliferation for all SLC-treated samples compared to the negative control. As 
expected, the SLC+LAM1-116 mAb-treated sample showed the highest 
enhancement in proliferation. The summary data (Figure 17) demonstrates 
statistical significance in the 36 hour samples with the spleen and PLN showing 
significant variances of P=0.003 (n=8) and P=4.9x10-5 (n=9), respectively. In the 
splenic sample, Tukey’s HSD test for the SLC+LAM1-116 mAb treated sample 
vs. the SLC alone treatment or SLC+LAM1-101 mAb treated was significant with 
P=0.007 (n=8) and P=0.009 (n=8), respectively. The same trend was seen in the 
PLN with comparison between the SLC and SLC+LAM1-116 mAb groups 
showing a P=6.2 x10-5 (n=9), and the SLC+LAM1-116 to SLC+LAM1-101 mAb 
treated groups showing a P=9.2x10-4 (n=9). 
 For the CD8+ T cell analysis for 72 hour proliferation, all proliferation levels 
increased, similar to the 72 hour CD4+ proliferation. Representative data shown 
in Figure 18 demonstrates similar increases for all SLC-treated samples, with the 
LAM1-116 mAb-treated sample showing the highest enhancement in 
proliferation. Variance between treatments after data transformation was 
39 
 
 
 
significant for both the spleen and PLN, with P=0.0004 (n=5) and P=0.002 (n=5), 
respectively (Figure 19). In the PLN, post hoc tests showed HSD values to be 
significant between the SLC+LAM1-116 mAb-treated sample vs. SLC alone or 
SLC+LAM1-101 mAb treatment (n= 5, P=0.002; n=5, P=0.02, respectively). In 
the spleen, Tukey’s HSD test also showed significant differences between the 
SLC+LAM1-116 mAb treated samples vs. the SLC-treated alone sample (n=5, 
P=0.0005) or the SLC+LAM1-101 mAb-treated sample (n=5, P=0.002). Thus, 
these findings of L-selectin-mediated increases in CD8+ T cell proliferation are in 
good agreement to the results seen in CD4+ T cells. 
v. Samples treated with SLC and LAM1-116 mAb showed higher frequencies of 
CD4+ and CD8+ T cells at the terminal divisions for samples reaching asymptotic 
growth. 
 
 To address the limitations of samples reaching asymptotic growth at the 
72 hour time point, and thereby providing no distinguishable differences between 
samples, we decided to analyze dividing subpopulations (Figure 20). To this end, 
we isolated 3 samples from both the spleen and PLN that showed at least 3 
discernible division peaks. These peaks had to show a MFI of at least half of the 
preceding peak to be considered for analysis. Without exception, SLC+LAM1-
116 mAb-treated samples showed a higher frequency of both CD4+ and CD8+ T 
cells in the terminal division (P5, Table 1). In splenic CD4
+ T cells, the LAM1-116 
mAb-treated sample showed a doubling of cells in the G5 subpopulation vs. all 
other treatments. A similar result was also observed for the splenic CD8+ T cells.  
 In the PLN, CD4+ T cells treated with LAM1-116 mAb showed the highest 
means compared to all other treatments. CD8+ T cells in the same tissue also 
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showed similar increases in cell frequency at the terminal division, when 
compared to SLC treatment alone or the SLC+LAM1-101 mAb treatment group. 
Unfortunately, the variability between experiments along with the small n, did not 
allow us to find any significant differences. Transforming the data set similar to 
the steps outlined in the previous experiments provided no relief from the large 
variances or did not eliminate normality outliers. Using power analysis 
(power=0.80) an n=44.5 would be required to overcome this statistical quandary. 
vi. Frequency of L-selectin+ cells and enhanced proliferation do not show a 
correlation. 
 
 While virtually all naïve T cells express high levels of L-selectin, subsets of 
effector and memory T cells express low to negative levels (95). Using Pearson’s 
correlation, we then embarked on determining whether the frequency of L-
selectin positive cells effected proliferation. All transformed proliferation numbers 
were compared to the frequency of L-selectin positive cells in each sample, 
corresponding to all cell populations regardless of tissue origin and subset. 
Pearson’s r for L-selectin frequency vs. 36 hour proliferation showed an r=0.01, 
indicating no relationship between the two variables whatsoever. The same was 
detected in the 72 hour time point with r=0.00. However, visualizing the data set 
(Figure 21), one can see a minor positive r value for L-selectin frequency vs. the 
72 hour proliferation levels. The presence of outliers may have negated this 
effect, with a steep decline of correlation at the highest levels of proliferation. 
Interestingly, there is significant positive correlation between the 36 and 72 hour 
proliferation time points with an r=0.37, P=0.0085. An alternative approach to 
discern whether the frequency of L-selectin+ cells affect proliferation would be to 
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subject the samples to multi-variate analysis, perhaps by using MANOVA or 
using a general linear model (GLM). However, because the frequency L-selectin+ 
cells between tissues and subsets do not have an appreciable difference, 
analysis of L-selectin+ cell effects may prove unattainable.  
4. Discussion 
 The bulk of the results from the current studies point to a general 
contribution of L-selectin activation to T cell proliferation. This effect is most likely 
directly related to L-selectin activation since the antibody used was a monoclonal 
antibody that has previously been shown to bind to the activation (i. e., lectin) 
domain of L-selectin (10). This is in comparison to the lack of response of cells 
treated with the control antibody that also binds L-selectin but at a region 
distinctly distant from the activating site. The current results also show that 
activation through CCR7 via SLC contributes to increases in TCR-mediated 
proliferation. However, while SLC activation alone did induce a modest increase 
in T cell proliferation, the highest level of proliferation was exclusively found in 
the L-selectin-activated samples. In regards to subset analysis, because of the 
transmigration step prior to TCR-induced proliferation, it was possible that 
subsets could show a distinct preference for chemotaxis based on mAb 
treatment or chemokine used. This would have a dire consequence on subset 
bias. If the SLC+LAM1-116 mAb treatment induced higher levels of CD4+ or 
CD8+ T cell migration in comparison to the SLC- or SLC+LAM1-101 mAb-treated 
samples, the sheer difference in cell proportion between treatments could be the 
simple explanation for any observed proliferative effects. However, subset 
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analysis of treatment populations indicated homogenous populations negating 
any population effects that may have rendered our analysis invalid (Figure 11). 
 In the 36 hour post-TCR stimulation analysis, proliferation levels were 
significantly higher in the LAM1-116 mAb-treated, SLC transmigrated samples. 
The PLN bulk sample showed a distinct higher increase in proliferation compared 
to the spleen bulk sample (Figure 7). This is reasonable because of the higher 
proportion of T cells in this tissue, which in turn have higher expression levels of 
L-selectin (4). Similarly, CD4+ T cells from the PLN also showed a better 
response to LAM1-116 mAb treatment compared to the corresponding splenic 
sample. This most likely reflects the finding that 88±3% of PLN CD4+ cells 
expressed high levels of L-selectin in comparison to 80±2% for splenic CD4+ T 
cells (data not shown). In regards to CD8+ T cells, the increase in proliferation 
was opposite of that observed for CD4+ T cells. Specifically proliferation of 
splenic CD8+ T cells treated with LAM1-116 mAb surpassed that similarly treated 
PLN CD8+ T cells by at least 10% (131±6% vs 120±2%, respectively). This was 
unexpected due to higher levels of L-selectin+ CD8+ T cells in the PLN. However, 
the nature of the CD8+ T cells in each tissue also has to be taken into account. 
CD8+ T cells of the central memory phenotype may be present in higher numbers 
in the spleen and therefore may exhibit a more responsive proliferative effect 
compared to naïve cells that have just recently transmigrated to the PLN. Central 
memory cells are products of clonal expansion during antigenic encounter which 
possess the ability to migrate between the blood and parenchyma. This 
population has been known to be more reactive and more efficient in clearing 
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antigenic challenges (96). Furthermore, the difference in L-selectin+ CD8+ T cells 
that are between compartments were negligible at less than 2%, with the PLN 
residents at the high end (data not shown). Another possible explanation for this 
difference is the nature of the microenvironment from where the cells originated. 
T lymphocytes and therefore CD8+ T cells are not the dominant cell type in the 
spleen. In the transmigrated population analyzed via flow cytometry, less than 
50% of splenic cells were T cells as compared to almost 80% of PLN cells 
(Figure 11). A possible population that may create an environment in which CD8+ 
T cells from the spleen proliferate better may be the CD56dim natural killer cells. 
This NK subset is more abundant in the spleen and has been shown to be more 
prolific in responding to antigen and produces high levels of pro-inflammatory 
cytokines at early stages of antigenic encounter (97-98). Another interesting 
finding came from comparing CD4+ versus CD8+ T cells in the same tissue. 
Although, the CD8+ T cells in the spleen showed a better response to L-selectin-
mediated signaling compared to splenic CD4+ T cells, this was not the case in 
the PLN. In the PLN, CD4+ T cells proliferated better than CD8+ T cells following 
L-selectin engagement (Figure 13 and 14). We expected CD8+ T cells to have a 
more robust response to LAM1-116 mAb treatment because of the frequency of 
L-selectin positive cells for this subset (93.5±0.5%) in comparison to the CD4+ T 
cells (87±1%) (data not shown). Additionally, experiments using bulk populations 
also showed a better predisposition of PLN lymphocytes to proliferate compared 
to the spleen (Figure 7). A possible explanation for this difference is the larger 
proportion of CD4+ T cells in the PLN transmigrating population (Figure 11). This 
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PLN CD4+ T cell population is distinct from that of the spleen due to the higher 
frequency of L-selectin positive cells. Another contributing factor to the 
enhancement in CD4+ T cell  proliferation in this tissue may be the higher density 
of dendritic cells (99). Dendritic cells are extremely efficient at presenting antigen 
and activating CD4+ T cells and thus their increased presence in the PLN 
samples may contribute to the observed enhanced proliferation.  
 In the 72 hour samples, the results were much clearer. As expected, all 
LAM1-116 mAb-treated samples produced the greatest proliferative responses 
(Figures 9, 15 and 19). In the bulk populations, both tissue samples were almost 
identical in proliferation enhancement. As discussed before, we expected a more 
robust response in the PLN proportional to the increased frequency of L-selectin+ 
cells. It must be noted that at the 72 hour time point, most of the samples 
regardless of treatment had reached 90% or higher levels of proliferation 
(Figures 8, 14 and 18). Therefore, the differences between tissues were less 
distinct. Regardless of this convergence on asymptotic growth for the bulk 
populations, our expectations were supported for cell subsets in all tissues. In the 
spleen and PLN, the CD8+ T cell subset exhibited a higher degree of proliferation 
enhancement over the CD4+ T cell subset, consistent with the frequency of L-
selectin+ cells (Figures 15 and 19). PLN residents also showed a higher level of 
proliferation enhancement over their splenic counterparts, again consistent with 
L-selectin+ cell frequency (Figures 15 and 19). 
 To determine the preference of subsets reaching a terminal division, we 
utilized samples reaching asymptotic growth and compared the frequency of 
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each T cell subset per terminal division (Figure 21, Table 1). This particular 
experiment was only performed with samples reaching asymptotic growth 
because samples reaching submaximal growth do not exhibit the same number 
of cell divisions and thus a true comparison between samples cannot be made. 
In all tissue subsets, L-selectin activation resulted in more cells reaching terminal 
division (Table 1). Furthermore, CD4+ spleen T cells, which contained the lowest 
frequency of L-selectin+ cells, also displayed the lowest rates of terminal division. 
As expected, CD8+ T cells and PLN residents displayed the highest rates of 
terminal division with the PLN CD8+ T cells exhibiting the highest rate. However, 
the variance between samples made the data set inconclusive but with trends 
following our predictions. The variance problem can be easily solved by 
increasing the sample size. However, at the 72 hour time point post-stimulation, 
finding treatments that have reached asymptotic growth is not definite. This 
problem could be easily solved by moving time points farther forward, possibly to 
4 or 5 days post stimulation. Another problem that arose from this study was the 
non-linear relationship between the frequency of L-selectin+ cells and 
proliferation as outlined in Figure 21. Just by visual inspection, no correlation 
between L-selectin frequency and the two time points could be detected. In the 
36 hour proliferation time point, no correlation could be ascertained statistically or 
visually (Figure 21A and 21C). In the 72 hour data set, a positive correlation 
between L-selectin frequency and proliferation was apparent at the lower levels 
that increased proportionally as L-selectin frequency increased (Figure 21E). 
However, there was a decline in the relationship in the latter parts of the figure, 
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thus, negating the initial positive correlation. Interestingly, there was a clear 
positive correlation between the 36 hour and 72 hour time points of proliferation, 
indicating that cells that have proliferated better at 36 hours also proliferated 
better at the 72 hour time point. 
 Aside from the minor issues outlined previously, our data shows that L-
selectin activation contributes to the ability of T cells to proliferate in response to 
signaling. Because this study is singularly based on phenotypic analysis in vitro, 
we are hampered by our inability to pinpoint a mechanism for such proliferative 
effects. To this end, we propose the following mechanistic model.  
 It has been shown that the cytoplasmic tail of L-selectin associates with 
CaM (100-102). The cytoplasmic tail is also known to associate with ezrin radixin 
moesin (ERM) proteins (101, 39). Based on these observations, a model of L-
selectin multimerization involving CaM and ERM binding adjacent L-selectin 
molecules was proposed (101). It is known that L-selectin activation oftentimes 
involves ectodomain shedding (103-104), which in turn disrupts cytoplasmic tail 
associations. Subsequently, CaM and ERM proteins are released exposing the 
two serine residues in the cytoplasmic tail that in turn has been shown to be 
phosphorylated (84). What happens after? This phosphorylation step most likely 
mediates a response because it is difficult to understand why a molecule would 
be phosphorylated and not used.  
It has previously been shown that L-selectin can bind growth factor 
receptor-bound protein 2/son of sevenless (Grb2/SOS), and activate the Ras 
pathway (105). However, Grb2/SOS binding requires a Src homology 2 (SH2) 
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binding domain which is not present in the L-selectin cytoplasmic tail. It should be 
noted that SH2 domains bind to phosphorylated tyrosine residues and L-selectin 
does possess a terminal tyrosine residue in the cytoplasmic domain that can 
potentially be phosphorylated. However, this is unlikely because of its terminal 
position and the absence of an SH2 domain. A likely candidate that could bridge 
L-selectin and Grb2/SOS binding is the 14-3-3 protein. The cytoplasmic terminal 
amino acid sequence of mouse L-selectin (RRLKKGKKSQERMDDPY), and 
human L-selectin (RRLKKGKKSKRSMNDPY), both show a potential 
homologous sequence to the putative 14-3-3 binding mode 1 sequence of 
RSXpSXP (106, the bold serine residue indicates required phosphorylation). 
Although the sequence of the L-selectin tail is not 100% complementary to the 
putative binding domain, it must be noted that 14-3-3 can bind to some proteins 
displaying a dissimilar sequence as in the case of insulin-like growth factor-1 
(107), or insulin receptor substrate-1 (108). The ability of 14-3-3 to bind to 
regions without complete complementarity seems to rest on its ability to utilize a 
14-3-3 dimer as well as dual phosphoserine residues for partner binding (109). It 
is then possible that 14-3-3 binding to the L-selectin tail can recruit Grb2/SOS. It 
must be noted that Grb2 and 14-3-3 possess SH2 and Src homology 3 (SH3) 
domains, respectively. It has been shown that SH2 and SH3 domains can 
interact with each other (110-112).  
In light of the possibility of L-selectin+14-3-3 binding and the eventual 
recruitment of the Grb2/SOS dimer, one can now see that the potential of Ras 
sarcoma protein (Ras) involvement is quite likely. The Grb2/SOS and Ras 
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relationship has been firmly established. SOS serves as a guanine exchange 
factor (GEF), and its primary role is in the transition for Ras to exchange its 
bound GDP to GTP (113-115). The GDP to GTP transition activates Ras (116). 
Importantly, it must be noted that the same paper by Brenner in 1996, also 
showed Ras involvement. The involvement of Ras is expected with the diversity 
of signaling molecules that are activated during L-selectin activation. Specifically, 
reports have shown that L-selectin activation involves Rac protein (117), p38 
mitogen activated protein kinase (MAPK) (118), urokinase receptors (119), light 
chain kinase (Lck) (120), in addition to others. The Ras pathway is logical 
because most of the signaling molecules outlined above are downstream events 
of Ras activation. Furthermore, Ras is an oncogenic protein responsible for 
proliferation signals in tumorigenic cells, in parallel to our proliferation assays.  
 The proposed mechanism of phosphorylated L-selectin+14-3-
3+Grb/SOS+Ras is a very plausible one in relation to enhancement that has 
been reported in other cell mechanisms. In the Subramanian paper (6), an L-
selectin signaling contribution to CCR7-mediated chemotaxis was described. 
SOS is a guanine exchange factor, responsible for the GDP-GTP transition, in its 
function, as well as the function of other molecules. The G subunit of G-protein 
coupled receptors (GPCR) requires a transition from GDP to GTP, which is 
normally catalyzed by a GPCR ligand docking to the receptor. It is foreseeable 
that SOS can also induce this GDP-GTP exchange in GPCR’s, activating them in 
the absence of ligand, and in our case enhancing the activity of CCR7 in the 
presence of its ligand, SLC. This indirect relationship between L-selectin and 
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proliferation by way of Ras also explains the absence of significant correlation in 
our study (Figure 21). The TCR-induced proliferation may have masked any 
contributions to proliferation by L-selectin, with TCR-induced proliferation being 
much stronger than L-selectin-induced proliferation. This could also explain the 
small amounts of LAM-116 mAb-induced proliferation observed relative to the 
control.  
 The proposed mechanism outlined above directly supports the L-selectin-
induced enhancement in TCR-mediated proliferation outlined in this thesis as 
well as the chemotactic enhancement reported previously (6). Further work to 
clarify the molecular mechanisms must be undertaken to provide a better 
understanding of the underlying mechanism and lend additional support for our 
proposed model.  
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Figure 6. Representative proliferation histograms of spleen and PLN lymphocytes at 36 hours post-TCR stimulation. Cells were isolated from 
Spleen (A-D) and PLN (E-H), and stained with 0.25 M of CFSE (intensity shown on the X axis).  Some samples were treated with 10 g/mL of the 
L-selectin activating mAb, LAM1-116, before transmigration in the presence of 500 ng/mL of SLC (SLC+LAM1-116, C and G). Other samples were 
transmigrated to the same concentration of SLC with no mAb treatment (SLC, B and F) or treated with 10 g/mL of a control mAb, LAM1-101 
(SLC+LAM1-101, Figures D and H). Cells that transmigrated to media alone without mAb treatment are considered negative (Figures A and E). All 
4 treatment subsets were subsequently induced to proliferate in the presence of anti-CD3 and anti-CD28 mAbs in a 96 well plate. Numbers in red 
indicate the frequency of actively proliferating cells. Proliferating cells were identified as the population flanked by a non-CFSE stained sample 
(dashed line) and a non-proliferated CFSE stained sample (dotted line). Both controls were from the same population as the treated samples and 
were analyzed at the same time point. Results are representative of 10 and 9 experiments for spleen and PLN, respectively. 
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Figure 7. Summary data of spleen and PLN lymphocyte proliferation at 36 hours post-TCR stimulation. Results are from experiments shown in 
Figure 6. All numbers (mean±SEM) are in comparison to a proliferated and CFSE-stained control sample exposed to media alone 
(Treatment/Control*100). In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=10, P=0.04; n=9, 
P=0.01; respectively. In the spleen, post hoc Tukey HSD tests showed no significant difference between the LAM1-116 treated sample compared 
to the sample treated with SLC alone, n=10, P=0.06, or the sample treated with SLC along with the control mAb, LAM1-101, n=10, P=0.09. In the 
PLN, the differences between groups were significant in both cases: n=9, P=0.01; n=9, P=0.04; respectively. Statistical analysis was performed 
using R version 2.15.2. * indicates PAnova<0.05. ** indicates PTukey HSD<0.05. ns indicates not significant. 
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Figure 8. Representative proliferation histograms of spleen and PLN lymphocytes at 72 hours post-TCR stimulation. Cells were isolated from 
Spleen (A-D) and PLN (E-H), and stained with 0.25 M of CFSE (intensity shown in the X axis). Samples were treated as described in Figure 6 
and analyzed 72 hours following TCR stimulation. Numbers in red indicate the frequency of actively proliferating cells. Proliferating cells were 
identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-proliferated CFSE stained sample (dotted line). Both 
controls were from the same population as the treated samples and were analyzed at the same time point. Results are representative of 6 and 7 
experiments for spleen and PLN, respectively. 
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Figure 9. Summary data of spleen and PLN lymphocyte proliferation at 72 hours post-TCR stimulation. Results are from experiments shown in 
Figure 8.  All numbers (with SEM bars) are in comparison to a proliferated and CFSE-stained control sample exposed to media alone 
(Treatment/Control*100). In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=7, P=0.015; n=6, 
P=0.016; respectively. In the spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to 
the sample treated with SLC alone, n=7, P=0.02, or the sample treated with SLC along with the control mAb, LAM1-101, n=7, P=0.04. In the PLN, 
the differences between groups were significant in both cases: n=6, P=0.05; n=6, P=0.02; respectively. Statistical analysis was performed using R 
version 2.15.2. * indicates PAnova<0.05. ** indicates PTukey HSD<0.05.  
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Figure 10. Representative subset dot plots of transmigrated cells. Cells were isolated from spleen (A-D) and PLN (E-H), and treated as described 
in Figure 6. After chemotaxis, wells for the same treatment were pooled and subset frequencies for CD4
+
 T cells (x axis) and CD8
+
 T cells (y axis) 
in the transmigrated population were determined using flow cytometry. Numbers in red indicate the frequency of cells in each quadrant. No 
significant variations between treatment groups were detected. Results are representative of 7 experiments.  
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Figure 11. Summary data of transmigrated cell subset analysis. Data was obtained from the experiments shown in Figure 10 (n=7 independent 
experiments). ns indicates not significant. 
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Figure 12. Representative histograms of proliferating CD4
+
 T cells at 36 hours post-TCR stimulation. Cells were isolated from spleen (A-D) and 
PLN (E-H), and treated as described in Figure 6 except that the samples were labeled for CD4 expression. Numbers in red indicate the frequency 
of actively proliferating CD4
+
 T cells. Proliferating cells were identified as the population flanked by a non-CFSE stained sample (dashed line) and 
a non-proliferated CFSE stained sample (dotted line). Both controls were from the same population as the treated samples and were analyzed at 
the same time point. Results are representative of 7 independent experiments per tissue. 
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Figure 13. Summary data of CD4
+
 T cell proliferation at 36 hours post-TCR stimulation. Results are from experiments shown in Figure 12. All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
In both the spleen and PLN, variances (one-way ANOVA) between treatments was significant, n=7, P=0.01; n=7, P=0.0009; respectively. In the 
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 mAb treated sample compared to the sample treated with 
SLC alone, n=7, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=7, P=0.03. In the PLN, the differences between 
groups were significant in both cases: n=7, P=0.01; n=7, P=0.02; respectively. Statistical analysis was performed using R version 2.15.2. * 
indicates PAnova<0.05. ** indicates PTukey HSD<0.05. 
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Figure 14. Representative histograms of proliferating CD4
+ 
T cells at 72 hours post-TCR stimulation. Cells were isolated from Spleen (A-D) and 
PLN (E-H), and treated as described in Figure 12. Numbers in red indicate the frequency of actively proliferating cells. Proliferating cells were 
identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-proliferated CFSE stained sample (dotted line). Both 
controls were from the same population as the treated samples and were analyzed at the same time point. Results are representative of 5 
independent experiments. 
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Figure 15. Summary data of proliferating CD4
+
 T cells at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 14. All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=5, P=0.01; n=5, P=0.03; respectively. In the 
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC 
alone, n=5, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=5, P=0.03. In the PLN, the differences between 
groups were significant in both cases: n=5, P=0.05; n=5, P=0.04; respectively. Statistical analysis was performed using R version 2.15.2. * 
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.  
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Figure 16. Representative histograms of proliferating CD8
+
 T cells at 36 hours post-TCR stimulation. Cells were isolated from spleen (A-D) and 
PLN (E-H), and treated as described in Figure 6 except that the samples were labeled for CD8 expression. Numbers in red indicate the frequency 
of actively proliferating cells. Numbers show increased proliferation in all SLC treated cells, with the LAM1-116 mAb treated sample displaying the 
highest proliferation. Proliferating cells were identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-
proliferated CFSE stained sample (dotted line). Both controls were from the same population as the treated samples and were analyzed at the 
same time point. Results are representative of 8 and 9 independent experiments for the spleen and PLN, respectively. 
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Figure 17. Summary data of CD8
+
 T cell proliferation at 36 hours post-TCR stimulation. Results are from experiments shown in Figure 16.  All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=8, P=0.003; n=9, P=4.9x10
-5
; respectively. In the 
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC 
alone, n=8, P=0.007, or the sample treated with SLC along with the control mAb, LAM1-101, n=8, P=0.009. In the PLN, the differences between 
groups were significant in both cases: n=9, P=6.2x10
-5
; n=9, P=9.2x10
-4
; respectively. Statistical analysis was performed using R version 2.15.2. * 
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.  
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Figure 18. Representative histograms of proliferating CD8
+
 T cells at 72 hours post-TCR stimulation. Cells were isolated from spleen (A-D) and 
PLN (E-H), and treated as described in Figure 16. Numbers in red indicate the frequency of actively proliferating cells. Proliferating cells were 
identified as the population flanked by a non-CFSE stained sample (dashed line) and a non-proliferated CFSE stained sample (dotted line). Both 
controls were from the same population as the treated samples and were analyzed at the same time point. Results are representative of 5 
independent experiments per tissue. 
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Figure 19. Summary data of proliferating CD8
+
 T cells at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 18.  All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
In both the spleen and PLN, variances (one-way ANOVA) between treatments were significant, n=5, P=0.0004; n=5, P=0.002; respectively. In the 
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC 
alone, n=5, P=0.0005, or the sample treated with SLC along with the control mAb, LAM1-101, n=5, P=0.002. In the PLN, the differences between 
groups were significant in both cases: n=5, P=0.002; n=5, P=0.02; respectively. Statistical analysis was performed using R version 2.15.2. * 
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.  
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Figure 20. Representative histogram of a 72 hour sample post-TCR stimulation that had reached asymptotic growth. Samples were treated as 
described in Figure 6. The area bound by the negative control (dotted and dashed line) and positive control (dashed line) was analyzed for 
divisions (Progeny:P0-P5).Divisions must exhibit mean fluorescence intensity of approximately half of the preceding peak to be considered for 
analysis. The frequency of CD4
+
 and CD8
+ 
T cells in each division were then analyzed.  Result is representative of 3 independent experiments per 
tissue. 
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Figure 21. Correlogram of L-selectin positive cell frequency versus 36 and 72 hour proliferation. Data is from experiments shown in Figures 6-19. 
L-selectin (LAMFrequency)  from both CD4
+
 and CD8
+
 T cells were then compared to proliferation levels using Pearson’s correlation. Dot plots 
illustrates proliferation levels (x axis) versus L-selectin
+
 cells (y axis) at both 36 (A) and 72 (B) hours. Results were statistically not significant with r 
values of 0.00 and 0.01 (n=50), respectively. Interestingly high proliferation levels at the 36 hour time point positively correlates with proliferation 
levels at 72 hours (n=50, r=0.37, P=0.0087), shown in figures  D and F. Figures C and E are best fit lines for the dot plots for the 36 and 72 hour 
time points respectively. Statistical analysis was performed using R version 2.15.  
LAMFrequency 
A B
  A 
C D 
E F 
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Table 1. Population analysis of cell division population at 72 hour post-TCR stimulation. Results are from experiments shown in Figure 20 (n=3). 
Results between treatments in the G4 and G5 populations, although showing greater frequencies of CD4
+
 and CD8 
+   
T cell subsets in the 
SLC+LAM1-116 treated samples, were not significant.  
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Chapter 3: Characterization of T cell apoptosis during simultaneous 
activation of L-selectin and CCR7 
 
1.  Research design 
The effects outlined in Chapter 2 of L-selectin-mediated enhanced TCR-
induced proliferation could be a product of two effects separately or in synchrony. 
Specifically, these effects could be a result of: 1) populations that truly respond 
by increasing cell proliferation, 2) cell samples showing a decrease in the rate of 
cell death (apoptosis) and finally, 3) a contribution by both phenomena. In 
relation to the effects listed above, signaling through several adhesion molecules 
has been implicated in lowering rates of apoptosis (121-122). Interestingly, in 
some reports, apoptosis and proliferation were inversely related following 
activation of adhesion molecules (123-124). Transmigration as a cellular process 
has also been shown to inhibit apoptosis. This is true for neutrophils exposed to 
stimulation by bacterial lipopolysaccharide (125). However, in the previously 
mentioned paper, L-selectin engagement was positively associated with 
apoptosis. By contrast, others studies have shown that the apoptotic rate of 
peripheral mononuclear cells was inversely related to L-selectin expression 
levels (126). To ascertain whether our observed increased proliferative effect of 
L-selectin engagement was from either a combination of enhanced proliferation 
and lower apoptosis or a stand-alone effect; a corresponding assay for apoptosis 
was utilized using propidium iodide (PI). PI staining can be used as a 
fluorescence method for determining cell viability. PI can intercalate double 
stranded nucleic acids if the cell membrane is permeable. Thus, cells that are 
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apoptotic and have compromised cellular membranes allow PI to diffuse in, 
resulting in a nuclear fluorescence that can be detected.  
 
2. Materials and Methods 
i. Cell Isolation and Sample Treatment 
 Please refer to chapter two for protocols for cell isolation and experimental 
conditions.  
 
ii. Apoptosis Assay 
 In some experiments, cells from the same time points were analyzed for 
apoptosis with PI (Molecular Probes, Carlsbad, CA) staining. Cells prepared as 
described in the previous experiments and exposed to the same conditions were 
analyzed. Cell subset antibody staining was performed as previously described, 
along with addition of 5 g/mL of PI. In this case, antibody and PI staining 
incubations were performed in the dark at room temperature for 30 minutes. This 
assay was performed at the 36 and 72 hour time points, post-TCR stimulation, in 
parallel to the proliferation assays described in chapter 2. To detect cells 
undergoing stages of apoptosis, only cells that were in the live resting 
lymphocyte and actively dividing lymphoblast gate were considered. Thus, cells 
in the lymphocyte/lymphoblast gate which were also PI positive were considered 
to be apoptotic cells. The frequency of apoptotic cells of the sample treated with 
media alone was compared to the other treatment samples. A ratio of less than 
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100% indicated a decrease in apoptosis whereas numbers higher than 100% 
indicated an increase in apoptosis. 
iii. Data Analysis 
 
After analyzing the raw data for homogeneity of variance with the Bartlett 
test and normality with a Q-Q line plot, deviations were detected that proved the 
raw data unusable. To correct for these departures from normality and variance 
all data were normalized as follow: 
%Apoptotic Improvement = (frequency of apoptotic cells in the treated 
sample/frequency of apoptotic cells in the untreated sample)* 100 
Transformed data were subjected to normality and variance tests, through 
Q-Q line plot and Bartlett tests, respectively. No significant departures were 
noted or the residuals of the outliers did not impact the outcome of the factors. 
Data were then analyzed with one-way ANOVA. If data sets showed significant 
variance (p < 0.05), further analysis between groups was performed using the 
Tukey Honestly Significant Difference (HSD) test. A P value of less than 0.05 
was considered significant. Pearson correlation was also performed between 
apoptosis versus frequency of L-selectin positive cells. All data analysis was 
performed using R 2.15.2 (R Foundation for Statistical Computing, Vienna, 
Austria). 
3. Results 
i. CD4+ T cell apoptosis at 36 hours post-TCR stimulation.  
 To ascertain if anti-apoptotic activity can also contribute to the increase in 
TCR-induced proliferation described in Chapter 2, subset apoptotic effects were 
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analyzed. In the CD4+ T cell subset at 36 hours, no detectable differences 
between samples were detected regardless of tissue origin. In the spleen, CD4+ 
T cells that were also PI positive (apoptotic cells, upper right hand quadrants, 
Figures 22 A-D), show results that are relatively similar to each other with 6.16% 
(negative), 6.59% (SLC), 6.2% (SLC+LAM1-116) and 6.8% (SLC+LAM1-101). 
This was also the case with CD4+ T cells from the PLN with apoptotic cell 
frequencies of 4.83% (negative), 5.25% (SLC), 5.28% (SLC+LAM1-116) and 
5.73% (SLC+LAM1-101) (Figures 22 E-H). Transforming the data relative to 
control, similar to the approach taken for proliferation in chapter 2 also showed 
the same result. In this regard, % Apoptotic Improvement<100%, indicates a 
lower rate of apoptosis relative to control. No variances were found between 
treatment groups in the spleen (n=4, P=0.511) or PLN (n=4, P=0.275). 
Interestingly, looking at the summary data (Figure 23), a trend of increased 
apoptosis for all treatment groups, with the LAM1-116 mAb-treated sample 
displaying the highest level, was observed. 
ii. CD4+  T cell apoptosis at 72 hours post-TCR  stimulation 
 The data from the apoptotic analysis of CD4+ T cells at 72 hours post-
stimulation showed a distinct departure from the 36 hour time point. Looking at a 
representative spleen dot plot, one can see the LAM1-116 mAb-treated sample 
displaying the lowest frequency of CD4+ apoptotic cells at 6.5% (Figure 24). This 
is in comparison to the control- (9.75%), SLC- (9.73%) and SLC+LAM1-101 mAb 
(9.21%) -treated cells (Figures 24, A-B and D). This was similar to the results 
from PLN CD4+ T cell  samples at the same time point, which displayed an 
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apoptotic frequency of 15.99% for the SLC+LAM1-116 mAb treatment compared 
to 20.97% (negative), 17.2% (SLC) and 18.81% (SLC+LAM1-101) (Figures 24 E-
H). The transformed summary data are shown in Figure 25. The LAM1-116 mAb- 
treated CD4+ splenic sample showed a mean % apoptotic improvement±SEM of 
73.44±7.30, compared to 87.89±4.56 (SLC) and 84.62±4.40 (SLC+LAM1-101) 
(Figure 25). The variance between groups was significant at P=0.007 (n=4), with 
post hoc Tukey HSD tests showing significant difference between the LAM1-116 
mAb- and SLC-treated samples (n=4, P=0.01) or the SLC+LAM1-101 mAb-
treated sample (n=4, P=0.02). In the PLN, the values were similarly decreased in 
the LAM1-116 mAb-treated sample (77.10±5.31) compared to the SLC-treated 
sample (89.11±5.02) and the SLC+LAM1-101 mAb treated sample (88.01±3.68). 
The variance between groups was similarly significant at P=0.01 (n=4) and the 
Tukey HSD tests between the LAM1-116 mAb-treated sample compared to the 
SLC treatment (n=4, P=0.01) and SLC+LAM1-101 mAb treatment (n=4, P=0.02) 
both showed significance (Figure 25). These data indicate that activation through 
L-selectin exerts an anti-apoptotic effect in CD4+ T cells that is discernible at 72 
hours post-TCR stimulation. 
  
iii. CD8+ T cell apoptosis at 36 hours post-TCR stimulation 
 Similar to the results for CD4+ T cells, CD8+ T cell apoptosis was 
unaffected by L-selectin activation at the 36 hour post-TCR stimulation time 
point. The representative dot plot for this experiment shows splenic CD8+ T cell 
apoptotic frequencies with minor variations at 8.95% (negative), 9.43% (SLC), 
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8.9% (SLC+LAM1-116) and 9.92% (SLC+LAM1-101) (Figure 26 A-D). The mean 
% Apoptotic Improvement±SEM (n=5) for this experiment confirms this lack of 
effect with SLC=112±2.77%, SLC+LAM1-116=134±9.35% and SLC+LAM1-
101=116±4.13% (Figure 27). The variance for the spleen and PLN were P=0.276 
and P=0.24, respectively (n=5 for both tissue). The representative PLN values 
shown in the dot plots are: 3.37% (negative), 9.21% (SLC), 3.26% (SLC+LAM1-
116) and 3.57% (SLC+LAM1-101) (Figure 26 E-H). Summary transformed data 
demonstrate the same results (Figure 27). Therefore, a modest increase in 
apoptosis was observed for all SLC-treated cells with the LAM1-116 mAb-treated 
sample exhibiting the highest response, albeit statistically insignificant. 
iv. CD8+ T cell apoptosis at 72 hour post-TCR stimulation 
Representative CD8+ T cell dot plots at 72 hour post-stimulation showed a 
general decrease in apoptosis with the LAM1-116 mAb-treated sample showing 
the biggest decrease (Figure 28). These results were surprising given that the 
opposite effect was found at the 36 hour time point, post-TCR stimulation. 
Specifically, splenic CD8+ T cells treated with SLC+LAM1-116 mAb showed 5.8% 
apoptosis, compared to 6.84% (negative), 7.63% (SLC) and 7.97% (SLC+LAM1-
101) (Figure 28A-D). The same relative decrease in apoptosis was also observed 
in  the representative PLN samples with 28.97% (negative), 24.75% (SLC), 
19.59% (SLC+LAM1-116) and 25.83% (SLC+LAM1-101) (Figures 28 E-H). 
Variances between transformed samples in the spleen were significant at n=4, 
P=0.004 (SLC=68.86±2.4%, SLC+LAM1-116=53±3.31% and SLC+LAM1-
101=71.5±3.06%) and in the PLN at n=4, P=2.15x10-6 (SLC=93±0.55%, 
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SLC+LAM1-116=84±0.74% and SLC+LAM1-101=92.69±0.27%) (Figure 29). 
These results show that activation through L-selectin results in an anti-apoptotic 
effect in CD8+ T cells that is detectable at 72 hours post-TCR stimulation. 
 
v. Correlation between L-selectin and apoptosis levels 
 Utilizing Pearson’s r, we then subjected all apoptotic values compared to 
all frequencies of L-selectin positive cells regardless of tissue origin and cell 
subset to a correlation test, coupled with a correlogram (Figure 30). The 
frequency of L-selectin positive cells was not correlated to the 72 hour rates of 
apoptosis (r=0.11, P=0.47) but interestingly in the 36 hour rates of apoptosis 
there was a significant negative correlation (r=-0.40, P=0.0045). Interestingly, the 
36 hour time point is when the rates of apoptosis were all increased across all 
treatments, with the LAM1-116 mAb treatment eliciting the greatest rate of 
apoptosis.  
4. Discussion  
 Unlike the proliferation results described in chapter 2, the apoptosis 
results are much less straightforward. At the 72 hour time point, all samples 
treated with the LAM1-116 mAb showed a significant decrease in apoptosis, 
compared to all other samples (Figure 25 and 29). Interestingly, the lowest level 
of apoptosis observed was in the CD8+ splenic T cell subset, contrary to our 
tissue origin prediction. We predicted the apoptotic effect would be more 
pronounced in the PLN, due to the higher frequency of L-selectin expressing 
cells in this tissue. It should be noted that T cells do not constitute the bulk of the 
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lymphocyte population in the spleen; rather B cells are the dominant lymphocytes 
in this tissue.  
 Analyzing our correlation data also shows no significant relationship 
between frequency of L-selectin positive cells and apoptotic rate at the 72 hour 
time point (Figure 30). However, a negative correlation between L-selectin 
frequency and apoptosis was detected at the 36 hour time point (Figure 30). This 
is in direct opposition to the summary data (Figure 23, 25, 27 and 29). Therefore, 
it is highly unlikely that there is any direct relationship between L-selectin 
frequency and apoptosis based on the present data. However, there may be a 
mechanistic reason behind these findings as discussed below.  
 At the 36 hour time point, our findings directly contradict our expectations. 
Specifically, LAM1-116 mAb treatment tended to induce higher levels of 
apoptosis in all samples regardless of tissue origin (Figures 23 and 27). It must 
be noted that initial TCR stimulation induced by cross linking CD3 can increase 
levels of apoptosis in a phenomenon described as activity induced cell death 
(AICD or ACD, 127-129). It should be noted that CD3 mediates initial activation 
of T cells and thus exerts its influence at early time points, similar to the 36 hours 
post-stimulation apoptosis analysis undertaken in this study. Thus, we can 
assume that the latter stages of cell proliferation are no longer mediated by CD3 
or its effects are no longer dominant. Despite CD3 activation explaining initial 
increases in apoptosis, what explains the decline in apoptosis observed in the 72 
hour post-stimulation samples? In light of the mechanism proposed in Chapter 2, 
the temporal basis of the initial increase in apoptosis followed by a decrease can 
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be explained. As discussed in Chapter 2, a possible mechanism for L-selectin 
signaling is through the Ras signaling pathway. We propose that Ras is recruited 
via a prototypical Grb2/SOS recruitment to the inner cell membrane, which in turn 
was mediated by 14-3-3 binding to the phosphoserine residues in the L-selectin 
tail. 14-3-3 has been shown to sequester pro-apoptotic factors in the cytoplasm 
through protein-protein interactions. The primary apoptotic factors sequestered 
by 14-3-3 includes but is not limited to: BCL-2/XL Associated Death promoter 
(130), BCL-2 associated x protein (131) and Forkhead box 01 transcription factor 
(FOXO, 132). If we consider the disruption of 14-3-3 interaction with pro-
apoptotic genes, we can certainly see a possible increase in apoptosis when 14-
3-3 protein leaves its pro-apoptotic partner and interacts with the phosphorylated 
L-selectin tail. This is reflected in the 36 hour apoptotic rates in the presence of 
L-selectin activation. However, what accounts for the 72 hour time point 
decrease in apoptosis? Again the L-selectin tail can point us in the right direction.  
 During L-selectin signaling one of the first molecules that is released from 
its interaction with the cytoplasmic tail is CaM. CaM has been shown to be an 
anti-apoptotic signal. CaM can counteract apoptosis by several mechanisms 
including but not limited to CaM dependent protein kinase 4 (133-134), CaM 
dependent kinase 2 (135-136) and via Protein Kinase B (137-138). At the 36 
hours post-TCR stimulation time point, it is possible that the apoptotic factors 
released from sequestration by the 14-3-3 protein could overcome the anti-
apoptotic effects of CaM. However, by the 72 hour post-TCR stimulation time 
point, it is possible that 14-3-3 together with CaM can exert an anti-apoptotic 
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effect that is detectable. This effect may be partly due to the proteolytic 
degradation of the L-selectin tail at the later time points. These temporal effects 
of 14-3-3 and CaM could explain the differences in the apoptotic rates observed 
at the 36 and 72 hours post-TCR stimulation time points. This complexity could 
also explain the lack or paradox of correlation between L-selectin activation and 
apoptosis at both time points. However, further biochemical analysis involving 
14-3-3 and CaM must be undertaken to support the proposed mechanism 
outlined above. 
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Figure 22. Representative dot plots of apoptotic CD4
+
 T cells at 36 hours post-TCR stimulation. Cells were isolated from spleen ( A-D) and PLN 
(E-H), and stained with 0.25 M of CFSE. Some samples were treated with 10 g/mL of the L-selectin activating mAb, LAM1-116, before 
transmigration in the presence of 500 ng/mL of SLC (SLC+LAM1-116, C and G). Other samples were transmigrated to the same concentration of 
SLC with no mAb treatment (SLC, Figures B and F) or treated with 10 g/mL of a control mAb, LAM1-101 (SLC+LAM1-101, D and H). Cells that 
transmigrated to media alone without mAb treatment are considered negative (A and E). All 4 treatment subsets were subsequently induced to 
proliferate in the presence of anti-CD3 and anti-CD28 mAbs in a 96 well plate (both mAb at 2g, with 5x10
4
 cells per well). Subsequently, cells 
were collected after 36 hours, and the subset (y axis) analyzed for apoptosis (Propidium Iodide positive cells, x axis). Numbers in red indicate cell 
percentages per quadrant. Results are representative of 4 independent experiments per tissue. 
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Figure 23. Summary data of CD4
+
 T cell apoptosis at 36 hours post-TCR stimulation. Results are from experiments shown in Figure 22. All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
Group variances are not statistically significant, with P values of 0.511 and 0.275 for spleen (n=4) and PLN (n=4), respectively. Statistical analysis 
was performed using R version 2.15.2. ns indicates not significant. 
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Figure 24. Representative dot plots of apoptotic CD4
+
 T cells at 72 hours post-TCR stimulation. Samples were treated as described in Figure 22 
and analyzed 72 hours post-TCR stimulation. Numbers in red indicate cell percentages per quadrant. Results are representative of 4 independent 
experiments per tissue. 
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Figure 25. Summary data of CD4+ T cell apoptosis at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 24. All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
In both the spleen and PLN, variances (one-way ANOVA) between treatments was significant, n=4, P=0.007; n=4, P=0.01; respectively. In the 
spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with SLC 
alone, n=4, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=4, P=0.02. In the PLN, the differences between 
groups were significant in both cases: n=4, P=0.01; n=4, P=0.02; respectively. Statistical analysis was performed using R version 2.15.2. * 
indicates PAnova<0.05. ** indicates PTukey HSD<0.05.  
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Figure 26. Representative dot plots of CD8
+
 T cell apoptosis at 36 hours post-TCR stimulation. Cells were treated as described in Figure 22. 
Numbers in red indicate cell percentages per quadrant. Results are representative of 5 independent experiments per tissue. 
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Figure 27.  Summary data of CD8
+
 T cell apoptosis at 36 hours post-TCR stimulation. All samples were treated as described in Figure 22. All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
Group variances were not statistically significant, with P values of 0.276 and 0.24 for spleen (n=5) and PLN (n=5), respectively. Statistical analysis 
was performed using R version 2.15.2. ns indicates not significant. 
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Figure 28. Representative dot plots of apoptotic CD8
+
 T cells at 72 hours post-TCR stimulation. Samples were treated as described in Figure 22 
and analyzed for apoptosis 72 hours post-TCR stimulation. Numbers in red indicate cell percentages per quadrant. Results are representative of 4 
independent experiments per tissue. 
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Figure 29. Summary data of CD8
+
 T cell apoptosis at 72 hours post-TCR stimulation. Results are from experiments shown in Figure 28. All 
numbers (with SEM bars) are in comparison to a proliferated and CFSE stained control sample exposed to media alone (Treatment/Control*100). 
In both the spleen and PLN, variances (one-way ANOVA) between treatments was significant, n=4, P=0.004; n=4, P=2.15x10
-6
; respectively. In 
the spleen, post hoc Tukey HSD tests showed significant difference between the LAM1-116 treated sample compared to the sample treated with 
SLC alone, n=4, P=0.01, or the sample treated with SLC along with the control mAb, LAM1-101, n=4, P=0.005. In the PLN, the differences 
between groups were significant in both case : n=4, P=5.5x10
-6
; n=4, P=9.3x10
-6
; respectively. Statistical analysis was performed using R version 
2.15.2. * indicates PAnova<0.05. ** indicates PTukey HSD<0.05.  
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Figure 30. Correlogram of L-selectin positive cell frequency versus 36 and 72 hour apoptosis. Data is from experiments shown in Figures 22-29. 
The apoptotic frequency ( x axis) from both CD4
+
 and CD8
+
 T cells were correlated to frequency of L-selectin
+
 cells (LAMlevels, y axis) in all cells 
from all tissues.  Dot plots (A, B and D) and their corresponding best fit line (C, E and F) are shown. Pearson’s correlation is significantly negative 
between L-selectin
+
 cell frequency (LAMlevels, y axis) and decreases in apoptosis (x axis) with n=50, r=-0.40, P=0.0045,at 36 hours (Figures B 
and E). All other correlations were not significant. Statistical analysis was performed using R version 2.15.2.
A B 
C D 
E F 
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Chapter 4: Conclusions 
 The current studies show that L-selectin engagement in conjunction with 
the presence of a transmigration signal via CCR7, enhances subsequent TCR-
induced proliferation and protects activated T cells from late apoptosis. As 
alluded to in the discussions of the previous chapters, we propose a model that 
involves the 14-3-3 adaptor protein. Although speculative in nature, 14-3-3 
binding can explain the temporal differences observed in proliferation 
enhancements and apoptotic protection. It is known that the cytoplasmic tail of L-
selectin contains one (for mice) or two (for humans) serine residues that are 
phosphorylated by PKC isoforms (84). It is also known that these potential 
phosphoresidues are protected by CaM and ERM binding during homeostatic 
conditions (101). It must be noted that CaM and 14-3-3 proteins are both helical 
in structure, CaM with 7 helices and 14-3-3 with 9 (139-140). We propose that 
the phosphoserine residues can attract 14-3-3 binding. This binding can bridge 
Grb2/SOS and Ras association. SOS could then exchange the bound nucleotide 
of Ras from GDP to GTP, resulting in an activated Ras molecule (113). This 
activated Ras molecule could now induce kinase cascades resulting in an 
increase in signaling pathways including: the Raf/MEK/ERK (Extracellular Signal-
Regulated Kinases) pathway, the MEKK/SEK/JNK (Jun N-terminal Kinases) 
pathway, a PI3K (Phosphatidylinositol 3-Kinase)/Akt/NF-KappaB (Nuclear 
Factor-Kappa B) pathway, in addition to others (141-142). The ultimate purpose 
of this signaling collective is to drive T cell activation and proliferation. However, 
14-3-3 binding to the phosphorylated L-selectin cytoplasmic domain is not 
without a cost. 14-3-3 is known to bind and sequester apoptotic factors in the 
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cytoplasm (143); it is likely then that the cost of an increase in proliferation is also 
a concomitant increase in apoptosis which we detected at 36 hours post-TCR 
stimulation. At the 36 hour time point it is likely that there are two conflicting 
signals in terms of apoptosis, the 14-3-3 release of its pro-apoptotic partners and 
the release of the CaM from the L-selectin tail, an anti-apoptotic molecule. It is 
possible then that at the early time points, the apoptotic signal is greater than the 
anti-apoptotic signal. However, once the L-selectin tail has been proteolytically 
digested, 14-3-3 returns to the cytoplasm and sequesters the pro-apoptotic 
factors again. Furthermore, with CaM no longer able to interact with the L-
selectin tail, this molecule can add to the anti-apoptotic environment at 72 hours 
post-TCR stimulation. Figure 31 illustrates the model outlined above. 
 L-selectin’s primary role has always been the homeostatic recirculation of 
naïve T cells. However, studies have also shown its ability to serve as a signaling 
molecule, improving the immunogenic ability of leukocytes as well as enhancing 
adhesion steps downstream from its own. The 17 amino acid cytoplasmic domain 
may be an incidental signaling molecule. Through its phosphorylated form, it 
likely serves as a signaling scaffold for multiple pathways, in a temporal and 
spatial fashion. The usefulness and importance of such signaling ability may be 
lost in the in vitro context of this study. Specifically, we need to be aware that the 
signaling context of this study is in receptor saturated conditions (i.e., antibody 
ligation), conditions that may not be applicable in vivo. However, in less than 
saturated conditions, where a minimal repertoire of receptors are engaged, a 
scaffolding function may be important, especially in focal adhesions and the 
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immunological synapse. Further studies, especially in vivo are required, before 
such functions may be directly attributable to L-selectin.
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Figure 31. Proposed mechanism of L-selectin contribution to proliferation and apoptotic protection.  In A, L-selectin is dimerized by CaM and ERM 
interaction. 14-3-3 sequesters  BAD from the mitochondria and SOS and Ras are not associated with each. In B, L-selectin’s interaction with Cam 
and ERM is disrupted by ligand binding, the cytoplasmic tail is phosphorylated which recruits 14-3-3. 14-3-3 can now mediate SOS-Ras interaction 
which activates Ras resulting in higher levels of proliferation. However, BAD is now free to translocate to the mitochondria resulting in higher levels 
of apoptosis. In C, after the initial levels of L-selectin activation has plateaued and the tail is proteolytically digested, CaM can phosphorylate 
excess free BAD, resulting in 14-3-3 interaction, sequestering BAD again from the nucleus. 
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